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SUMMARY
The GRACILE syndrome is a metabolic disorder characterized by fetal 
growth retardation, lactic acidosis, iron overload, tubulopathy, cholestasis and 
death in early infancy. It has an autosomal recessive mode of inheritance and is 
part of the Finnish disease heritage. In Finland, the incidence is at least 1:47 000. In 
this study we localized and identified the gene underlying the GRACILE 
syndrome, which serves as a starting point for revealing the pathogenesis of this 
metabolic disease. This study has also produced DNA diagnostics for this fatal 
disease, enabling prenatal diagnosis and carrier testing for the Finnish GRACILE 
families.   
The GRACILE gene was initially localized by a genome scan, using 
DNA samples from only nine patients, followed by conventional linkage analysis 
in eight nuclear families. The locus assignment to chromosome 2q33-37 was 
confirmed by LD analyses, and the critical markers were organized by RH 
mapping. Ancestral haplotype analysis revealed one founder haplotype shared by 
all GRACILE chromosomes and restricted the critical region between markers 
D2S2179 and D2S2244. 
The physical length of the critical chromosomal region was 1.3 Mb, and 
it contained two interesting candidate genes, ABCB6 and BCS1L. Lactic acidosis of 
the patients would suggest mitochondrial dysfunction, and both of these genes 
encoded proteins involved in mitochondrial respiratory function. In addition, 
ABCB6 was known to be linked to mitochondrial iron metabolism and to 
maintenance of the stability of mitochondrial DNA. ABCB6 was excluded as the 
causative gene for the GRACILE syndrome on the basis of the sequence, Northern 
blot and haplotype analyses. In BCS1L, however, all the Finnish GRACILE 
patients had a homozygous 232A>G mutation resulting in an S78G amino acid 
change. Sequencing of BCS1L in three British patients, whose symptoms closely 
resembled those of the Finnish patients, revealed five different mutations, including 
the Finnish S78G mutation. Pulse-chase experiments performed in COS-1 cells 
indicated that the S78G amino acid change results in instability of the polypeptide, 
and yeast complementation studies revealed a functional defect in the mutated 
BCS1L.
The function of Bcs1p, the yeast homolog of BCS1L, has been studied in 
detail. Bcs1p is an inner mitochondrial membrane protein and functions as a 
chaperone in the assembly of mitochondrial respiratory chain complex III. In 
humans, BCS1L has a related function, since both our British patients and 
previously described Turkish patients with BCS1L mutations unequivocally had a 
defect in complex III. In the Finnish GRACILE patients, however, the complex III 
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activities were normal or only slightly reduced. Presumably BCS1L has another, 
unknown but essential, cellular function, putatively involving iron metabolism.   
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REVIEW OF THE LITERATURE 
The GRACILE Syndrome 
GRACILE syndrome (OMIM 603358) is a lethal metabolic disorder with 
autosomal recessive inheritance. The acronym is composed of the first letters of the 
characteristic symptoms and findings: Growth Retardation, Aminoaciduria, 
Cholestasis, Iron overload, Lactic acidosis and Early death. The syndrome is the 
newest member of the Finnish disease heritage, a group of 36 monogenic diseases 
that are enriched in Finland (Norio et al. 1973; Norio 2000). The article by Norio et 
al. in 1973 mentioned five infants with fulminant lactic acidosis, the disease in 
these patients probably being the GRACILE syndrome. A comprehensive 
description of the disease entity, based on a series of 17 infants, was published by 
Fellman et al. in 1998. Since 1985, altogether 22 affected infants have been reliably 
diagnosed in 16 Finnish or Finnish-born families, and the male/female ratio of the 
patients has been 7/15. According to the 13 affected infants diagnosed in 1991-
2000, the incidence of the GRACILE syndrome in Finland is at least 1/47,000. 
Clinical Features 
The growth of all the affected infants was severely retarded, the average 
birth weight being only 1700 g, corresponding to an SD score of -3.8 for 
gestational age. The average birth length was 43 cm, and head circumference 31 
cm. Despite the extreme growth restriction, fetal distress was uncommon, and the 
patients were born near to or at term. At birth, the infants had a normal umbilical 
pH, and the first minute Apgar score was normal, but during the first day of life 
they developed severe lactic acidosis. On admission to intensive care, the mean 
arterial blood pH was 7.0 (normal range 7.35-7.43), the mean lactate 12.2 mmol/l 
(normal range 0.7-1.8), the mean pyruvate 120 µmol/l (normal range 40-70) and 
the mean lactate/pyruvate ratio 103 (normal <25). Despite intensive care and alkali 
therapy, half of the GRACILE patients died of fulminant acidosis between the ages 
of 1 and 12 days. The other half of the infants survived for 1-4 months. Their 
acidosis fluctuated, and their weight gain was poor (median 29 g/week). The 
patients did not have any dysmorphic features, but they had a similar worried-
looking facial expression and wrinkled skin due to the absence of subcutaneous fat. 
(Fellman et al. 1998). 
All the GRACILE patients had nonspecific Fanconi-type aminoaciduria. 
Low thrombo-test values and increased conjugated bilirubin and aminotransferase 
concentrations indicated mild to moderate hepatic dysfunction. The muscle tone 
was within the normal range, and no neurological symptoms or neuropathological 
abnormalities were found. Hemoglobin concentrations and reticulocyte counts 
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were normal, and no major cardiovascular, pulmonary or gastrointestinal problems 
were observed. (Fellman et al. 1998). 
Histopathological findings  
The pathological findings in 17 Finnish GRACILE patients have recently 
been described. The most prominent histopathological changes were present in the 
liver. In all except one case, the liver showed microscopic cholestasis. The 
extrahepatic bile ducts were open. The livers of the neonates were macroscopically 
unremarkable, but in most of them there was a paucity of interlobular bile ducts, 
which may be the reason for the cholestasis. In the patients who died at over 1 
month of age, the livers showed a macroscopically green color and increased 
firmness, and the microscopic findings were steatosis and fibrosis. In most cases, 
the pancreas showed mild to moderate interstitial fibrosis and exocrine atrophy. 
Most of the patients had nephrocalcinosis, which is a relatively common finding in 
many disorders of infancy (Karlowicz and Adelman 1998). Tubular dysgenesis was 
observed in the kidneys of four patients, the amount of the proximal tubules being 
reduced to one-tenth of the controls. (Rapola et al. 2002). 
Iron metabolism 
One of the essential findings in the GRACILE syndrome is iron 
overload, including liver hemosiderosis, free plasma iron, and abnormal levels of 
proteins involved in iron transfer and storage (Fellman et al. 1998; Fellman et al. 
2000). During the neonatal period, the livers of the affected infants contain 
extensive amounts of stainable iron both in the hepatocytes and in the Kupffer 
cells. After the age of one month, the stainable iron disappears or clearly decreases 
from the hepatocytes, but in the Kupffer cells moderate amounts of iron are still 
present. Electron microscopy of two liver biopsy samples revealed typical 
hemosiderin granules surrounded by numerous ferritin particles in the hepatocytes. 
Iron accumulation has not been detected in the parenchymal cells of any organ 
except the liver in the GRACILE patients, but iron-containing macrophages are 
typically frequent in the spleen, and mild or moderate amounts of siderotic 
macrophages have also been detected in the lymph nodes, thymus, lungs and 
pancreas. (Rapola et al. 2002). 
GRACILE patients have free plasma iron and significantly decreased 
transferrin concentration in the serum, transferrin saturation being increased 
(Fellman et al. 1998; Fellman et al. 2000). The serum ferritin concentration is 
increased tenfold as compared to controls. It is not yet known whether the iron 
accumulation in this syndrome is the primary metabolic defect, or is secondary to 
the liver disease. The reduction in plasma transferrin concentration is unlikely to be 
the fundamental defect, since atransferrinemia and hypotransferrinemia typically 
14
do not cause problems in newborns, the main finding later in life being anemia 
(Hayashi et al. 1993; Beutler et al. 2000).  
GRACILE syndrome differs clearly from neonatal hemochromatosis, 
another lethal disorder characterized by liver hemosiderosis in the newborn period 
(Fellman et al. 1998; Rapola et al. 2002). In neonatal hemochromatosis, the 
hemosiderosis is abundant in several parenchymal organs in addition to the liver, 
but not in the reticuloendothelial cells (Knisely et al. 1987; Murray and Kowdley 
2001). The liver failure is more fulminant than in the GRACILE patients, causing 
hypoalbuminemia, hypoglycemia, coagulopathy, ascites, hyperbilirubinemia and 
low transaminase levels in the newborn period. Instead, profound acidosis and 
severe fetal growth retardation are not typical of neonatal hemochromatosis. The 
inheritance pattern of neonatal hemochromatosis is not known. This rare disease 
has been reported in siblings with healthy parents, suggesting autosomal recessive 
inheritance, but also in half-siblings with the same mother, suggesting maternal 
inheritance (Verloes et al. 1996).  
Two GRACILE patients have been treated by administrations of 
apotransferrin followed by exchange transfusions. The aim of the treatment was to 
reduce the toxic effects of free iron. Transferrin saturation and free plasma iron 
were decreased in both the treated infants, and no side effects were observed. 
However, the infants died later at the ages of ten and eight weeks. (Fellman et al. 
2000).   
Mitochondrial investigations 
Lactic acidosis suggests mitochondrial dysfunction. The lactate/pyruvate 
ratio in the GRACILE patients is increased, and they do not have ketoacidosis or 
organic aciduria (Fellman et al. 1998). Thus the lactacidosis would be likely to 
result from a defect in the mitochondrial respiratory chain (Scriver et al. 2001a). 
However, no distinct abnormalities have been found in mitochondrial 
investigations of the GRACILE patients (Fellman et al. 1998). The polarographic 
oxygen consumption studies implied normal respiratory chain function, and 
measurements of the activity of the respiratory chain enzyme complexes revealed 
only a slight, nonspecific decrease in complex I. No deletion or depletion of 
mitochondrial DNA was found in the muscle biopsy samples analyzed by Southern 
blots. The mitochondria also appeared normal in both the liver and muscle 
specimens analyzed by electron microscopy (Rapola et al. 2002).  
Non-Finnish patients
GRACILE patients with precisely the same symptoms and findings as 
described in the Finnish patients have not been reported elsewhere so far. However, 
three British patients have been described with a disease course closely resembling 
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that of the Finnish infants (Birch-Machin et al. 1989; Morris et al. 1995). The 
infants had moderate growth retardation, lactic acidosis, aminoaciduria and 
cholestasis, and died at the ages of 2, 42 and 105 days. However, there were a few 
differences from the Finnish disease entity. The British patients had muscle 
hypotonia, and one of them had seizures. In addition, a clear complex III defect 
was demonstrated in the enzyme activity measurements of the skeletal muscle 
mitochondria of the patients. Iron metabolism was not studied in the British cases.   
The Human Genome Project 
The Human Genome Project (HGP) is an international collaborative 
research program whose goal is the complete mapping and understanding of the 
human genes and genome. It is led by the National Human Genome Research 
Institute (NHGRI), which was established in 1989 at the National Institutes of 
Health (NIH) in USA. Other contributors are the United States Department of 
Energy (DOE) and numerous universities and other research facilities in the USA, 
the United Kingdom, France, Germany, Japan and China. The Human Genome 
Organization (HUGO), established in 1988, is an international organization 
coordinating the different national projects in order that the analysis of the human 
genome may be achieved as rapidly and effectively as possible. HUGO has also 
published several statements concerning the ethics of genetic research, for example 
concerning the collection of DNA samples, patenting of DNA sequences, and 
cloning. The HUGO Gene Nomenclature Committee approves and designates the 
symbols and names for novel genes. The goals for the HGP, initially defined in 
1990, were: 1) mapping and sequencing the human genome, 2) mapping and 
sequencing the genomes of model organisms, 3) data collection and distribution, 4) 
ethical and legal considerations, 5) research training, 6) technology development, 
and 7) technology transfer. (NHGRI and HUGO web pages; Strachan and Read 
1999a). (Internet addresses of the organizations and databases mentioned in this 
chapter are provided in the electronic database information section.)  
The important achievements of HGP in the early 90’s included 
production of dense genetic maps based on microsatellite markers, which were 
considerably less laborious to genotype than the RFLP markers used earlier 
(Weissenbach et al. 1992; Dib et al. 1996), and construction of the first physical 
maps covering the human genome (Cohen et al. 1993; Hudson et al. 1995). The 
main emphasis of the sequencing projects of the HGP was at first on the coding 
sequences, rather than on the genomic DNA. The cDNA libraries of different 
human tissues were randomly sequenced to produce expressed sequence tag (EST) 
sequences, which were subsequently mapped to the physical maps. By 1998, 
42 000 ESTs representing 30 000 human transcripts were mapped to the human 
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genome by the international RH mapping consortium (Deloukas et al. 1998), and 
the goals for years 1998-2003 were to produce full-length cDNA sequences of the 
human genes, as well as the complete human genomic sequence (NHGRI web 
pages).
February 15th, 2001 was an important day in the history of the HGP. On 
that day the article “Initial sequencing and analysis of the human genome” was 
published in Nature by the International Human Genome Sequencing Consortium. 
The sequence was not in its final form: the coverage of the draft sequence was 
approximately 94% of the 3200 Mb human genome, and approximately 26% of the 
genomic sequence was in its finished form, including two completely sequenced 
chromosomes, numbers 21 and 22. The sequencing of the human genome had 
progressed faster than anticipated: over roughly fifteen months in 1999-2000 the 
coverage of the sequence had increased from 10% to more than 90%. The 
sequencing strategy used by HGP was “hierarchical shotgun sequencing”. The 
genomic DNA of anonymous individuals was cloned as 100-200 kb fragments, 
mostly using bacterial artificial chromosome (BAC) vectors. BAC clones were 
mapped and organized to large clone contigs, and individual clones were selected 
for shotgun sequencing. Sequence fragments were then assembled to reconstruct 
the sequence of the whole genome. Since the BAC clone contigs were positioned 
along the chromosomes by anchoring them with markers from existing genetic and 
physical maps, gross errors in the sequence assembly were not likely to occur 
despite the many repetitive sequences (at least 50%) in the human genome. 
(International Human Genome Sequencing Consortium 2001). 
At the same time as the initial analysis of the human genome was 
published by HGP in Nature, Science published the article “The Sequence of the 
Human Genome” by Venter et al. This sequence was produced by Celera, a 
commercial company, and the sequence has not been freely available even after the 
publication of the article, but the company sells licences to use the sequence 
database. Celera was able to produce the raw sequence data even faster than the 
HGP laboratories by the “whole genome shotgun sequencing” approach. The 
whole genome was sequenced randomly and assembled automatically, without 
laborious mapping of the genomic clones (Venter et al. 2001). However, Celera 
was able to utilize the sequencing and mapping results produced by HGP, since 
academic, publicly funded institutions of HGP daily released all the sequences 
produced to freely accessible internet databases. The competition about the initial 
sequencing of the human genome between HGP and Celera finally led to a joint 
press conference on June 26th 2000, when they both claimed to have sequenced 
90% of the human genome, and to an agreement to publish the first analysis of the 
sequence simultaneously (NHGRI web page).  
17
The biggest surprise in the analysis of the human genome was that it was 
estimated to contain only 30 000 – 40 000 protein-coding genes (previous estimates 
being near 100 000), which is only about twice as many as in the nematode worm 
Caenorhabditis elegans or the fruitfly Drosophila melanogaster. However, the full 
set of proteins encoded by the human genome is more complex than those of 
invertebrates. First, the genes are more complex, with more alternative splicing 
generating a larger number of protein products. Secondly, the protein domains and 
motifs are more innovatively combined in vertebrates, as compared with 
invertebrates. (International Human Genome Sequencing Consortium 2001).     
Besides the sequencing of the human genome, much has been 
accomplished in the era of the sequencing of other organisms The sequencing of 
the first eucaryotic genome, the budding yeast Saccharomyces cerevisiae (genome 
size 12 Mb), was completed in 1996, and the genomes of Caenorhabditis elegans 
(97 Mb) and Drosophila melanogaster (120 Mb) were sequenced in 1998 and 
2000, respectively (Goffeau et al. 1996; The C. elegans Sequencing Consortium 
1998; Adams et al. 2000). Mapping of the mouse genome was performed with very 
much the same strategy as mapping of the human genome, but with every step 
following a couple of years later. The sequencing of the mouse genome is in 
progress (NCBI and Celera web pages). The genomes of the model organisms 
serve as an outstanding tool for the recognition and comparison of the genes and 
their regulatory elements, as well as the protein domains. They also provide tools 
for functional analyses of the genes and proteins. (Strachan and Read 1999a; 
International Human Genome Sequencing Consortium 2001). 
The development of the laboratory methods used in molecular biology 
has also been very rapid during the last ten years. Although the basic method used 
in DNA sequencing is still the dideoxy sequencing approach, invented 25 years ago 
(Sanger et al. 1977), the development of the automated fluorescence-based systems 
and capillary electrophoresis has facilitated substantially both sequencing and 
genotyping. Besides stimulating the rapid development of laboratory techniques, 
the HGP has produced well organized databases for gene, genome and protein 
sequences (e.g. at NCBI, UCSC, and EBI) and numerous bioinformatics tools for 
processing of the vast amounts of sequence data.  
Publication of the draft human genome sequence was only the starting 
point for understanding the function of the human genome, although the HGP has 
already produced several applications in medicine. The next goals are to close the 
gaps and produce a finished sequence covering all the chromosomes, to obtain a 
comprehensive collection of full-length human cDNA:s, and to identify the 
regulatory elements in the genome. More than two million single nucleotide 
polymorphisms (SNP), which play a crucial role in the identification of the genes 
responsible for complex diseases, have already been identified in the human 
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genome (dbSNP at NCBI web pages). The production of a more comprehensive 
SNP catalogue of the human genome, and further development of the array-based 
technologies for automated SNP genotyping are also challenges for the next few 
years. The ultimate goal is to move on to functional analyses of the proteins 
encoded by the genes (functional genomics and proteomics). (International Human 
Genome Sequencing Consortium 2001).  
Identification of human disease genes
There are several ways to identify genes underlying diseases with 
mendelian inheritance. Usually the disease gene identification process is a mixture 
of several strategies, but the different approaches can be classified to four main 
categories: functional cloning, candidate gene approach, positional cloning and 
positional candidate approach (figure 1). 
Functional cloning is the oldest method for disease gene identification. It 
was the only way to clone disease genes twenty years ago, when information about 
the human genome mapping was not available. Functional cloning is based on 
information about the basic biochemical defect causing the disease. The defective 
protein is purified, its amino acid sequence determined, and the cDNA of the 
disease gene is identified using oligonucleotides produced as a result of the amino 
acid sequence information. For example, identification of the hemophilia A gene 
followed this approach (Gitschier et al. 1984).  
The candidate gene approach also requires some knowledge of the 
pathogenesis of the disease or, for example, an animal model for the disease. This 
strategy means hypothesizing the right gene based on its known function and the 
symptoms of the disease. The gene can be tested directly for mutations in the 
patients, or for linkage in families. For example a few rare mutations resulting in 
defects in mitochondrial enzymes have been identified using this strategy 
(Bourgeron et al. 1994; Bourgeron et al. 1995; de Lonlay et al. 2001). So far, 
however, successes based solely on the candidate gene approach, without any clue 
to the location of the disease gene, have been rare. Maybe in the future, when all 
the human genes and their functions are known, this strategy will be more 
generally used. 
Development of the genetic and physical maps of the human genome 
enabled positional cloning. In this strategy the disease genes are identified through 
knowledge of their chromosomal location. If sufficient family material is available, 
the disease loci of Mendelian disorders can be identified with genetic mapping, and 
restricted with linkage disequilibrium or shared haplotype analyses in suitable 
populations. In some diseases, in which a clear functional defect is present in the 
patients’ cell lines, it has been possible to localize the disease gene by functional  
19
FUNCTIONAL 
CLONING
Functional information
Defective protein
Amino acid sequence
Nucleotide sequence
Identification of
disease gene
POSITIONAL 
CLONING
Chromosomal position 
of the disease gene
Locus restriction
Identification of novel
genes in the region
Nucleotide sequence
Amino acid
sequence
Identification of 
disease gene
Clues to 
protein function
CANDIDATE 
GENE APPROACH
Functional information
Candidate gene
(previcously
characterized)
Identification of 
disease gene
POSITIONAL 
CANDIDATE APPROACH
Chromosomal
position 
of the disease
gene
Some
functional
information
Positional
candidate genes
Identification of
disease gene
Figure 1  
The principles of the four main strategies for identification of disease genes.
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complementation, using microcell-mediated chromosome transfer, even though 
sufficient family material for linkage-based mapping has not been available 
(Cuthbert et al. 1995; Zhu et al. 1998; Seyda et al. 2001). Sometimes patients’ 
chromosomal rearrangements provide useful short-cuts for locating a disease gene. 
Positional cloning of a disease gene, followed by characterization of the defective 
protein, may be the first step in the process to reveal the molecular pathogenesis of 
a genetic disorder. “Pure” positional cloning has traditionally meant identification 
of novel genes by different laboratory methods from genomic clone contigs 
(physical mapping). At the end of the 80s and in the beginning of the 90s, this 
laborious approach was used to identify dozens of disease genes, for example the 
causative genes for Duchenne muscular dystrophy and cystic fibrosis (Worton and 
Thompson 1988; Rommens et al. 1989). During the 90s, the positional cloning 
methods developed rapidly, and the number of disease genes identified on the basis 
of their position in the genome grew exponentially (Collins 1995).  
The gene maps and sequence information produced by the HGP during 
recent years have gradually made the traditional physical mapping almost 
unnecessary. Nowadays, the predominant method of identifying disease genes is 
the positional candidate approach, a combination of the candidate gene approach 
and positional cloning. After assignment of the disease locus, it is usually 
unnecessary to identify novel genes in the region anymore. The sequences of 
positional candidate genes are available in the databases, and promising genes can 
be selected on the basis of their known function. If the exact function of a 
positional candidate gene or a predicted transcript is not known, information about 
the expression pattern of the gene, or about interesting homologies with other 
genes can be used as a guide to choosing suitable candidates. Especially amino acid 
sequence homologies to relevant proteins in model organisms can provide crucial 
clues to the identification of disease genes. Today also, positional cloning of 
disease genes can lead to the characterization of novel genes, but the cloning 
process, if needed, is nowadays carried out mostly “in silico”, being enormously 
much faster than the laboratory methods used five or fifteen years ago. (Strachan 
and Read 1999b). 
The number of identified disease genes is growing exponentially. As of 
October 1, 2001, the OMIM database contained 1,631 disorders in which the 
molecular basis had been identified at the DNA level. The total number of entries 
(genes, gene loci, allelic variants and phenotype descriptions of mendelian 
disorders) was 13,005. (Hamosh et al. 2002). 
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The Finnish disease heritage 
The concept of the Finnish disease heritage was introduced some 30 
years ago in an article entitled “Hereditary diseases in Finland; rare flora in rare 
soil”, which described some twenty inherited disorders occurring in Finland much 
more frequently than elsewhere (Norio et al. 1973). Nowadays, the number of 
diseases belonging to this group has doubled (table 1). Most of the diseases also 
occur elsewhere in the world, but their incidences are especially high in Finland 
due to founder mutations enriched in the population. Unravelling of the molecular 
defects underlying the Finnish disease heritage has proceeded very rapidly during 
the last decade. Circumstances in Finland are very advantageous for genetic 
research: The quality of the health care system is high, which has made exact 
clinical diagnoses possible even for very rare conditions. The patients and their 
families usually have a positive attitude towards research. Furthermore, 
comprehensive church registers provide excellent possibilities for genealogical 
studies. However, probably the most important factor which has led to the rapid 
identification of the disease genes is the genetic structure of the Finnish population. 
(de la Chapelle and Wright 1998; Peltonen et al. 1999; Norio 2000). 
Founder effect
The population of Finland is relatively young, and, for geographic and 
linguistic reasons, it has long remained rather isolated. There are several theories 
about the origin of the Finnish population. The recent analyses of Y chromosome 
haplotypes (Kittles et al. 1998), support a dual theory: The first settlers of Finland 
were Uralic speakers and arrived from the east some 4000 years ago. However, the 
majority of the genes in today’s Finnish population originate from small founder 
populations of Indo-European speakers who arrived from the south in the 
beginning of the first millennium. These founder populations expanded and spread 
along the coastlines of southern and western Finland. In the beginning of the 16th 
century, the Finnish population comprised approximately 250 000 inhabitants, who 
were concentrated in the coastal regions. Inhabitation of the inland area of eastern, 
central and northern Finland began in the 16th century, and for that reason this area 
is called by geneticists the late-settlement region (figure 2A). A substantial part of 
this migration began from the small south-eastern area of South Savo. Inhabitation 
of the late-settlement region formed small, rural communities, which remained 
relatively stable and isolated because of the long distances and low population 
density. After the great famine and epidemics, which killed approximately one 
third of the population between the years 1690-1730, the Finnish population has 
expanded rapidly, growing from approximately 250 000 inhabitants to today’s 
number of 5.2 million during three centuries. Since World War II, industrialization 
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Figure 2 
A) The internal migration movement of the 16th century from South Savo to the late 
settlement region of Finland, resulting in regional subisolates. B) Birthplaces of the great-
grandparents of the GRACILE patients on the map of Finland. Modified from Varilo 1999. 
has led to migration of the population from rural areas to urban communities, but 
there is still hardly any mixture between the subpopulations. (Norio 1981; de la 
Chapelle 1993; Peltonen et al. 1999; Varilo 1999; Norio 2000). 
The population history of Finland explains why some diseases are 
enriched in Finland, whereas others, for example cystic fibrosis and 
phenylketonuria, are very rare as compared with other Caucasian populations. 
Expansion of an isolated population after a population bottleneck can cause 
remarkable changes in allele frequencies (compared with the situation in larger, 
constantly mixing populations), because any mutation present in the founder 
population can either be enriched or practically disappear. If the mutation does not 
affect reproduction – and the carrier state of a mutation causing an autosomal 
recessive trait usually does not – the allele frequencies depend on chance. These 
phenomena are called the founder effect and genetic drift.  
In Finland there have been population bottlenecks both at the level of the 
population as a whole and on a smaller scale, especially in rural communities in the 
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sparsely populated areas of central, eastern and northern Finland. In many different 
Finnish diseases the distributions of the ancestors’ birthplaces reflect the 
population movements in Finland (Varilo 1999; Norio 2000). Approximately half 
of the diseases belonging to the Finnish disease heritage have a typical pattern, the 
ancestors being distributed in the late-settlement region, but hardly at all in the 
coastal regions (Norio 2000). The mutations in this group were most probably 
spread by the internal migration in the 16th century, and it has been estimated that 
most of these mutations were introduced into the Finnish population some 30-50 
generations ago (Varilo 1999). The second largest group includes six diseases: 
AGU, INCL, progressive myoclonus epilepsy, cartilage-hair hypoplasia, Batten 
disease and congenital nephrosis (Norio 2000). These are the most common 
disorders of the Finnish disease heritage, their incidences varying from 1:8000 to 
1:19 000. In these six diseases, the ancestors’ birthplaces are distributed fairly 
evenly across the whole country, but the late-settlement region is somewhat 
overrepresented as compared to the population density. The mutations causing 
these diseases had probably started to spread before the inhabitation of the inland 
regions, and it has been estimated that these mutations were introduced into the 
Finnish population some 70-120 generations ago (Peltonen et al. 1995; Varilo 
1999). Only on the maps of two diseases, diastrophic dysplasia and the Meckel 
syndrome, does the distribution of the ancestors correspond to the population 
density of Finland, covering the whole country, and being concentrated in southern 
and western Finland (Norio 2000). These are relatively common disorders, and the 
major mutations are most likely very old. Variant late infantile ceroid-
lipofuscinosis and progressive epilepsy with mental retardation represent the 
newest mutations, the ancestors’ birthplace pattern showing tight clustering in 
small areas (Norio 2000).   
Genealogy of the GRACILE syndrome 
The GRACILE syndrome is a typical example of a disease spread by the 
migration of the 16th century to the late-settlement region of Finland (figure 2B). 
The pedigrees of the affected families have been traced back to the mid-19th 
century, and the oldest to the late 17th century. No tight clustering of the ancestors’ 
birthplaces appears on the map of Finland, but almost all the ancestors were born in 
eastern or central Finland. In one family the parents were second cousins, and two 
earlier links between different nuclear families were established. (Fellman et al. 
1998).
Ancestral haplotypes and linkage disequilibrium 
In all the cloned Finnish disease genes, one major mutation is present in 
at least 70% of the disease chromosomes, and in most diseases one founder 
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mutation accounts for over 90% of the disease alleles (Peltonen et al. 1999; Varilo 
1999). Thus, identical DNA fragments, inherited from a single common ancestor, 
are to be found in the disease chromosomes of most patients (figure 3). Each 
fragment contains not only the disease mutation, but also a unique allele 
combination of the genetic markers in the immediate vicinity of the disease gene. 
This allele combination is called the ancestral haplotype. Ancestral haplotype 
analysis means restriction of the critical chromosomal region for the gene hunt by 
determining the chromosomal interval, which is completely conserved in the 
disease chromosomes. The deviation of the marker allele frequencies in the disease 
chromosomes, compared to the general population, is called linkage disequilibrium 
(LD), or allelic association. Mathematical models have been developed to test the 
significance of LD in disease alleles (Terwilliger and Ott 1994; Terwilliger 1995). 
DISEASE MUTATION
FOUNDER CHROMOSOME
N=5
N=10
N=50
THE CONSERVED PART OF 
THE FOUNDER CHROMOSOME
N = NUMBER OF GENERATIONS ELAPSED SINCE 
THE INTRODUCTION OF THE DISEASE MUTATION
Figure 3 
The basis for ancestral haplotype and LD analyses. A founder chromosome (black) with a 
disease mutation alters with time because of recombinations in successive meioses. After 
many generations, only a short chromosomal segment in the immediate vicinity of the 
disease gene represents the original founder chromosome in a descendant. Identification of 
the conserved region in the disease chromosomes of the patients through use of ancestral 
haplotype and LD analyses indicates the chromosomal location of the disease gene. 
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It is also possible to estimate the age of the mutation and the distance between the 
disease gene and a certain marker, using LD-based statistical tools (Hästbacka et al. 
1992; Lehesjoki et al. 1993).  
Utilization of LD and haplotype analyses has greatly enhanced the 
positional cloning projects of the Finnish disease genes, since these methods enable 
restriction of the critical chromosomal region to a very small interval. The age of  
the Finnish population is ideal for these analyses: young enough for the LD to be 
detected with a reasonable marker density, but old enough for the ancestral 
recombinations to restrict the critical region. Usually the conserved haplotype 
present in all the disease alleles spans some hundreds of kilobases, and the 
chromosomal interval, where a significant LD (p<0.0001) can be demonstrated in 
two-point analyses, is roughly comparable to this region. However, a suggestive 
LD (p<0.05) can be detected over long chromosomal intervals, up to 13 cM. The 
distances demonstrating LD in the different Finnish diseases have been observed to 
be in good accord with the results of genealogical studies: the younger mutations 
show longer chromosomal intervals with LD than the older ones. (Peltonen et al. 
1995; de la Chapelle and Wright 1998; Peltonen et al. 1999; Varilo 1999). 
Molecular genetics of the Finnish disease heritage 
The majority of the disease genes causing the Finnish diseases have been 
identified during the last decade, and at least the gene locus has been assigned for 
almost every disorder. Table 1 lists the diseases belonging to the Finnish disease 
heritage, the identified gene defects and gene loci, and the references. The methods 
used for identification of the disease genes have changed over the decade. In the 
beginning of the 90s, the predominating method was functional cloning and, for 
example, disease mutations resulting in gyrate atrophy and AGU were identified 
through knowledge of the defective protein. During the 90s, “pure” positional 
cloning, meaning identification of totally novel genes, was performed for example 
in the cloning of the genes responsible for diastrophic dysplasia and APECED. The 
strategy used in most projects has been a mixture of positional cloning and 
positional candidate approaches. Nowadays the positional candidate approach is 
practically the only method used.  
Identification of the disease loci and mutations has made DNA 
diagnostics possible in most of the diseases belonging to the Finnish disease 
heritage. Rapid, reliable and specific diagnoses aid the handling of the patients, and 
the possibility of prenatal diagnostics has been a relief for many families suffering 
from the most devastating disorders. However, identification of the causative 
mutation is only the starting point of a process which aims at resolving the 
pathogenesis of a disease, and finally developing treatment. Functional studies of 
the defective proteins in the Finnish diseases have markedly contributed to cell  
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Table 1 
Molecular genetics of the Finnish disease heritage. Included are those 36 diseases which 
Professor Reijo Norio listed as belonging to this entity in 2000 (Norio 2000). Almost all of 
these disorders are inherited by an autosomal recessive inheritance, with four exceptions: 
amyloidosis V and tibial muscle dystrophy are autosomal dominant traits, and 
choroideremia and retinoschisis are X-linked recessive traits. 
IDENTIFIED GENE DEFECTS 
Disease [OMIM number] Defective protein
Reference (Finnish 
mutations)
Gyrate atrophy (GA) [258870] Ornithine aminotransferase 
(OAT)
Mitchell at al. 1989 
Amyloidosis V [105120] Gelsolin (GSN) Levy et al. 1990, Maury et 
al. 1990 
Aspartylglucosaminuria (AGU) 
[208400] 
Aspartylglucosaminidase 
(AGA)
Ikonen et al. 1991 
Choroideremia [303100] Rab escort protein 1 
(REP1)
Sankila et al. 1992 
Nonketotic hyperglycinemia (NKH) 
[605899] 
Glycine decarboxylase 
(GLDC)
Kure et al. 1992 
Diastrophic dysplasia [222600] Solute carrier family 26, 
member 2 (SLC26A2) 
Hästbacka et al. 1994 
Infantile neuronal ceroid-lipofuscinosis 
(INCL) [256730] 
Palmitoyl protein 
thioesterase 1 
Vesa et al.1995 
Batten disease [204200] CLN3 protein The international Batten 
disease consortium 1995 
Hypergonadotrophic ovarian 
dysgenesis (ODG1) [233300] 
FSH receptor (FSHR) Aittomäki et al. 1995 
Congenital chloride diarrhea [214700] Solute carrier family 26, 
member 3 (SLC26A3) 
Höglund et al. 1996 
Progressive myoclonus epilepsy 
(EPM1) [254800] 
Cystatin B (CSTB) Pennacchio et al. 1996, 
Virtaneva et al. 1997 
APECED (autoimmune 
polyendocrinopathy – candidiasis – 
ectodermal dystrophy) [240300] 
Autoimmune regulator 
(AIRE)
Nagamine et al. 1997, The 
Finnish German APECED 
Consortium 1997
Congenital nephrosis [256300] Nephrin  Kestilä et al. 1998 
Variant late infantile neuronal ceroid-
lipofuscinosis (vLINCL) [256731] 
CLN5 protein Savukoski et al. 1998 
Retinoschisis [312700] Retinoschisin The retinoschisis 
consortium 1998 
27
Lysinuric protein intolerance (LPI) 
[222700] 
Solute carrier family 7, 
member 7 (SLC7A7) 
Torrents et al. 1999, 
Borsani et al. 1999  
Megaloblastic anemia 1 [261100] Cubilin (CUBN) Aminoff et al.1999 
Progressive epilepsy with mental 
retardation (EPMR) [600143] 
CLN8 protein Ranta et al. 1999 
Free sialic acid storage disease (Salla 
disease) [604369] 
Solute carrier family 17, 
member 5 (SLC17A5) 
Verheijen et al. 1999 
Cornea plana congenita (CNA2) 
[217300] 
Keratocan (KERA) Pellegata et al. 2000 
Mulibrey nanism [253250] TRIM37 Avela et al. 2000 
Polycystic lipomembranous 
osteodysplasia with sclerosing 
leukoencephalopathy (PLOSL) 
[221770] 
TYRO protein tyrosine 
kinase-binding protein 
(TYROBP) and TREM2 
Paloneva et al. 2000, 
Paloneva et al. 2002 
Cartilage-hair hypoplasia (CHH) 
[250250] 
RNA component of RNase 
MRP (RMRP) 
Ridanpää et al. 2001 
Usher syndrome, type III [276902] USH3A Joensuu et al. 2001 
Tibial muscle dystrophy (TMD) 
[600334] 
Titin (TTN) Hackman et al. 2002 
GRACILE syndrome [603358] BCS1-like (BCS1L) This study 
MAPPED LOCI 
Disease [OMIM number] Locus Reference
Cohen syndrome [216550] 8q Tahvanainen et al. 1994 
Infantile onset spinocerebellar ataxia (IOSCA) [271245] 10q Nikali et al. 1995 
Meckel syndrome [249000] 17q  Paavola et al. 1995 
Lethal congenital contracture syndrome (LCCS) [253310] 9q Mäkelä-Bengs at al. 1998 
Congenital lactase deficiency [223000] 2q Järvelä et al. 1998 
Muscle-eye-brain disease (MEB) [253280] 1p Cormand et al. 1999 
Hydrolethalus syndrome [236680] 11q Visapää et al. 1999 
DISEASE LOCUS NOT YET IDENTIFIED 
Disease [OMIM number]
Reference (clinical characterization
 of the disease)
RAPADILINO syndrome [266280] Kääriäinen et al. 1989 
PEHO syndrome [260565] Salonen et al. 1991 
Lethal arthrogyposis with anterior horn cell disease  Vuopala et al. 1995 
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biology. Unravelling of the molecular pathology in rare diseases can also lead to a 
better understanding of the pathogenetic mechanisms in the common diseases. For 
example, research on AIRE, the protein underlying APECED, can lead to 
discoveries in the field of autoimmune disorders in general, and functional studies 
of the CLN8 gene, mutated in progressive epilepsy with mental retardation, will 
most likely provide some clues to the molecular pathology of epilepsy. Two recent 
findings also provide interesting examples of the genetic mechanisms of Mendelian 
disorders: the gene mutated in cartilage-hair hypoplasia was discovered to encode a 
structural RNA molecule, instead of a protein, and the two genes underlying 
PLOSL, located in different chromosomes but resulting in identical phenotypes, 
have been found to encode proteins involved in the same cellular signaling 
complex. 
Nowadays, prenatal diagnosis is possible in most of the severe Finnish 
diseases. Families with index cases are offered genetic counselling and the 
possibility of antenatal diagnostics. However, most of the children with autosomal 
recessive diseases are born to parents who are unaware of their carrier state. Since 
the majority of the disease mutations causing the Finnish diseases have now been 
identified, and the array-based technologies have made identification of point 
mutations relatively cheap when performed in large numbers, screening of these 
mutations on the population level will soon be technically possible. One DNA 
array has already been developed and successfully used to determine the carrier 
frequencies of several diseases in different Finnish subpopulations (Pastinen et al. 
2001). In a questionnaire study evaluating the attitudes toward genetic testing 
among the general population in Finland, as well as among the relatives of the 
AGU patients, the attitudes were found to be favorable in general, but especially 
among the family members of the AGU patients (Hietala et al. 1995). In a pilot 
study, where carrier screening for the AGU mutations was offered to expectant 
couples in the framework of routine maternity health care in Helsinki, the 
participation rate was 95%, and the attitudes toward testing were mainly positive 
both before and after the gene test (Hietala 1998). Carrier screenings of fragile-X 
syndrome, AGU, INCL, and congenital nephrosis were offered to expectant 
couples in the pilot studies in Kuopio, where the participation rate was 
approximately 90% in all studies (Kallinen 2002). Thus, it seems that people in 
Finland mainly have a positive attitude toward the carrier screening of severe 
diseases.     
However, all medical screening programs may cause anxiety in some 
participants, even in those who are found to be negative, and thus it is not self-
evident that carrier screenings for very rare genetic diseases are justified. 
Combined screening for several mutations, using a DNA array, would especially be 
ethically problematic. On family-based screening, the genetic tests are always 
29
offered to patients or their relatives with thorough genetic counselling. It would be 
difficult to offer individual counselling covering every disease included in a 
screening “package” to everyone participating in a population-based screening. 
However, everyone participating should be aware of what kind of decision-making 
might lie ahead during pregnancies, if both parents proved to be carriers of the 
same mutation. Ideally, the screenings should be arranged before pregnancy, so 
that couples who do not want an abortion would have the possibility to consider 
other options, for example in vitro fertilization with pre-implantation diagnosis, or 
adoption. Furthermore, numerous people who would receive carrier diagnoses but 
would not be at risk of having affected children, would need genetic counselling to 
avoid unnecessary anxiety and worries. (Hietala 1998; Hiilesmaa and Salonen 
2000; Kere 2000; Kääriäinen 2000).  
Nuclear gene defects resulting in mitochondrial disease 
Mitochondrial diseases are a heterogeneous group of disorders, often 
characterized by morphological changes in the mitochondria, a defective 
respiratory chain and variable symptoms, ranging from severe metabolic disorders 
with onset in early infancy or childhood to late-onset adult myopathies. Mutations 
in mitochondrial DNA (mtDNA) are the most frequent cause of mitochondrial 
disease in adults, and during the last decade more than 100 pathogenic mutations 
have been identified in mtDNA. However, the mtDNA encodes only 13 of the 82 
subunits of the different complexes of the respiratory chain, as well as two rRNA 
molecules, and 22 tRNA molecules. All the other mitochondrial proteins are 
encoded by nuclear genes, and, in pediatric patients, most mitochondrial disorders 
are caused by mutations in nuclear genes. During recent years, an increasing 
number of nuclear mutations causing mitochondrial diseases have been identified. 
The symptoms of these diseases vary, depending on which mitochondrial functions 
are disturbed, and not all of them cause morphological changes in the 
mitochondria. Most of the nuclear gene defects causing mitochondrial diseases are 
inherited as autosomal recessive traits, but some are autosomal dominant traits, and 
some are X-linked. (Shoubridge 2001; Zeviani 2001). 
Table 2 lists the identified nuclear gene defects affecting the 
mitochondrial respiratory chain. These are mutations in genes encoding either the 
subunits of the respiratory chain enzyme complexes, the chaperones needed for 
assembly of the complexes, or the proteins involved in maintaining the stability of 
the mtDNA. The symptoms caused by these mutations are predominantly 
neurological. A typical example is Leigh disease, which is a fatal early-onset 
neurodegenerative disorder, characterized clinically by psychomotor retardation  
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Table 2
Diseases caused by nuclear gene defects affecting the mitochondrial respiratory chain, 
according to the reviews of Shoubridge 2001, Zeviani 2001, and Suomalainen and 
Kaukonen 2001. 
DISEASE 
DEFECTIVE 
PROTEIN
Defects in genes encoding structural components of the 
respiratory chain complexes
Leigh syndrome or leukodystrophy and myoclonic epilepsy  NDUFV1 (Complex I) 
Leigh syndrome NDUFS1 (Complex I) 
Cardiomyopathy and encephalomyopathy NDUFS2 (Complex I) 
Leigh syndrome NDUFS4 (Complex I) 
Leigh syndrome NDUFS7 (Complex I) 
Leigh syndrome NDUFS8 (Complex I) 
Leigh syndrome or late-onset optic atrophy, ataxia and myopathy SDHA (Complex II) 
Pheochromocytoma SDHB (Complex II) 
Hereditary paraganglioma SDHC (Complex II) 
Hereditary paraganglioma SDHD (Complex II) 
Defects in genes encoding assembly factors of the respiratory 
chain complexes
Tubulopathy, hepatopathy and encephalopathy BCS1L (Complex III) 
Leigh syndrome SURF1 (Complex IV) 
Hepatic encephalopathy SCO1 (Complex IV) 
Early-onset hypertrophic cardiomyopathy with encephalopathy SCO2 (Complex IV) 
Leukodystrophy and proximal tubulopathy COX10 (Complex IV) 
Defects in genes altering the stability of mtDNA
Autosomal dominant progressive external ophthalmoplegia 
(adPEO) 
ANT1 (adenine 
nucleotide translocase1) 
Autosomal dominant progressive external ophthalmoplegia 
(adPEO) 
Twinkle
Progressive external ophthalmoplegia (both autosomal dominant 
and recessive forms, adPEO and arPEO) 
DNA polymerase ?
Myoneurogastrointestinal encephalopathy (MNGIE) Thymidine 
phosphorylase 
Table 3 ?
Examples of diseases caused by mutations in nuclear genes encoding mitochondrial 
proteins with various functions.  
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DISEASE [OMIM number] DEFECTIVE PROTEIN REFERENCE 
X-linked sideroblastic anemia with 
ataxia [301310] 
ABCB7 (involved in the 
maturation of the FeS cluster 
proteins) 
Allikmets et al. 
1999 
X-linked sideroblastic anemia 
[301300] 
ALAS2 (involved in heme 
biosynthesis) 
Cox at al. 1994 
Friedreich ataxia [229300] Frataxin (involved in iron 
metabolism) 
Patel and Isaya 
2001 
Mohr-Traneberg syndrome (deafness-
dystonia syndrome), X-linked 
[304700] 
DDP1 (involved in the protein 
import to mitochondria) 
Koehler at al. 
1999 
Hereditary spastic paraplegia (SPG7) 
[602783] 
Paraplegin (metalloprotease, 
involved in protein turnover) 
Casari et al. 1998 
Hereditary spastic paraplegia 
(SPG13) [605280] 
HSPD1 (heat-shock 60-kd 
protein 1), mitochondrial 
chaperonin 
Hansen et al. 
2002 
Autosomal dominant optic atrophy 
[165500] 
OPA1 (may be involved in the 
control of mitochondrial 
morphology) 
Delettre et al. 
2000 
Pyruvate dehydrogenase deficiency 
(symptoms vary from fatal lactic 
acidosis to chronic neurological 
dysfunction) [312170, 245348, 
246900, 245349] 
Different components of the 
pyruvate dehydrogenase 
complex (E1, E2, E3, X-lipoate 
or pyruvate dehydrogenase 
phosphatase) 
Scriver et al. 
2001a  
Ornithine transcarbamylase 
deficiency (hyperammonia with 
various neurological symptoms) 
[311250] 
Ornithine transcarbamylase 
(enzyme of the urea cycle) 
Tuchman et al. 
1995 
Methylmalonic aciduria [251000] Methylmalonyl CoA mutase 
(involved in the metabolism of 
vitamin B12) 
Ledley and 
Rosenblatt 1997 
Fumarate hydratase deficiency 
(encephalopathy, dystonia, leucopenia 
and neutropenia), autosomal recessive 
inheritance [606812] 
Fumarate hydratase (enzyme 
of the citric acid cycle) 
Bourgeron et al. 
1994 
Dominantly inherited uterine fibroids, 
skin leiomyomata and papillary renal 
cell cancer [150800, 605839]  
Fumarate hydratase (enzyme 
of the citric acid cycle) 
The multiple 
leiomyoma 
consortium 2002 
32
and brainstem or basal ganglia dysfunction, and pathologically by bilateral lesions 
in the brainstem, basal ganglia, thalamus, and spinal cord. Interestingly, mutations 
in the subunits of complex II, as well as in fumarase, an enzyme of the citric acid 
cycle (The Multiple Leiomyoma Consortium 2002), have also been discovered to 
cause rare cancers. (Shoubridge 2001; Suomalainen and Kaukonen 2001; Zeviani 
2001).
Table 3 lists some examples of nuclear mutations affecting 
miscellaneous mitochondrial proteins. The first three, involved in mitochondrial 
iron metabolism, are discussed in greater detail in the next paragraph.  
Mitochondrial functions 
The principal task of the mitochondria is to generate ATP by oxidative 
phosphorylation. These organelles also perform numerous metabolic reactions: the 
citric acid cycle, the urea cycle, the degradation of fatty acids, and the synthesis 
and catabolism of several amino acids. In addition, heme, FeS clusters and various 
other enzyme cofactors and hormones are synthesized in mitochondria. 
Mitochondria also actively take part in programmed cell death machinery and act 
as intracellular calcium stores.  
Oxidative phosphorylation
An overview of human catabolic metabolism is presented in figure 4. 
The citric acid cycle, taking place in the mitochondrial matrix, includes a series of 
oxidation-reduction reactions that result in the oxidation of carbon fuels, usually in 
the form of acetyl CoA, to two molecules of carbon dioxide. These reactions also 
produce NADH and FADH2, which are energy-rich molecules containing a pair of 
electrons with high transfer and reducing potential. NADH and FADH2 are also 
formed in glycolysis and fatty acid oxidation. When the high-energy electrons of 
NADH and FADH2 are used to reduce molecular oxygen to water, energy is 
liberated and used to generate ATP. This is called oxidative phosphorylation, and is 
the major source of ATP in aerobic organisms. Oxidative phosphorylation is 
performed by the respiratory chain, which is located in the inner mitochondrial 
membrane and consists of four enzyme complexes participating in electron 
transfer, and a fifth enzyme complex, ATP-synthase. The flow of electrons from 
NADH and FADH2 through the respiratory chain to O2 leads to the pumping of 
protons out of the mitochondrial matrix into the mitochondrial intermembrane 
space. The resulting uneven distribution of protons generates a pH gradient and a 
transmembrane electrical potential that creates a proton-motive force. ATP is 
synthesized when protons flow back to the mitochondrial matrix through ATP- 
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Figure 4 
Simplified schematic presentation of the human catabolic metabolism. (CI-CIV = the 
mitochondrial respiratory chain complexes I-IV, CV = ATP synthase, Q = ubiquinone, C = 
cytochrome c)
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synthase. ATP then serves as an energy source in various cellular reactions. (Berg 
et al. 2001b). 
Complex III of the respiratory chain and BCS1L 
Complex III of the respiratory chain is presented here in greater detail, 
since it is the crucial complex in the GRACILE syndrome. Complex III 
(cytochrome bc1 complex or Q-cytochrome c oxidoreductase) of the respiratory 
chain is a dimer, with each monomer containing 11 subunits: core proteins I and II, 
six small subunits and three polypeptides involved in electron transfer: heme-
containing cytochrome b and cytochrome c1, and Rieske protein, which contains an 
FeS cluster. Cytochrome b is encoded by mtDNA, all other subunits being encoded 
by nuclear genes. Complex III catalyzes electron transfer between two mobile 
electron carriers, from ubiquinol to cytochrome c, and translocates protons from 
the mitochondrial matrix to the mitochondrial intermembrane space. (Berg et al. 
2001b).  
Isolated complex III defects are very rare, and are usually caused by 
point mutations in the cytochrome b gene, MTCYB. Mitochondrial point mutations 
are generally inherited maternally, whereas large rearrangements of mtDNA tend 
to be sporadic. MTCYB point mutations seem to be an exception to this rule, being 
mostly sporadic. They are usually heteroplasmic and restricted to the affected 
tissue. Typical manifestations of MTCYB mutations are exercise intolerance, 
proximal limb weakness and elevated lactate levels, sometimes associated with 
myoglobinuria (Andreu et al. 1999; Legros et al. 2001). More severe multisystem 
manifestations of MTCYB mutations, including symptoms of the central nervous 
system or cardiomyopathy, have also been reported (Valnot et al. 1999; Keightley 
et al. 2000; Wibrand et al. 2001).  
No mutations in the other structural subunits of complex III have been 
described, but mutations in BCS1L, a chaperone needed for the assembly of 
complex III, have been reported (de Lonlay et al. 2001). Bcs1p protein, the yeast 
homolog of the human BCS1L (BCS1-like) has been studied in detail. It is an inner 
mitochondrial membrane protein with a single transmembrane domain (Fölsch et 
al. 1996). A short N-terminus lies in the intermembrane space, and the bulk of the 
protein is located in the matrix. Unlike most mitochondrial proteins, the Bcs1p 
does not include an N-terminal targeting signal, but a positively charged segment 
of amino acids, located immediately C-terminally to the transmembrane domain, 
acts as an internal targeting signal (Fölsch et al. 1996). Bcs1p belongs to the 
conserved AAA protein superfamily (AAA - ATPases Associated with a variety of 
cellular Activities), and acts as an ATP-dependent chaperone maintaining complex 
III in a competent state for the assembly of Rieske FeS and Qcr10p subunits 
(Nobrega et al. 1992; Cruciat et al. 1999).  
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The human BCS1L gene has been cloned by searching the EST database 
with the yeast Bcs1p protein sequence, and it has been shown that the human 
BCS1L polypeptide is imported unmodified to the inner mitochondrial membrane 
(Petruzzella et al. 1998). The function of the human protein is related to that of 
yeast Bcs1p, since the five patients described by de Lonlay et al. had four different 
missense mutations in the BCS1L, and decreased complex III activity in the tissues. 
The symptoms of the patients varied, the essential findings being metabolic 
acidosis, tubulopathy, hepatic dysfunction and encephalopathy (de Lonlay et al. 
2001).
Formation of FeS clusters 
FeS clusters are important cofactors of many of the proteins in 
mitochondria, cytosol and nucleus. Synthesis of FeS clusters is an important house-
keeping function of mitochondria. The best-known FeS proteins are the FeS cluster 
-containing subunits of the respiratory chain complexes I, II and III, which serve as 
electron carriers. Recently, other FeS cluster-containing proteins, involved for 
example in the sensing of oxygen and iron, have also been studied intensively, as 
well as the mitochondrial proteins participating in the FeS cluster assembly. 
(Beinert and Kiley 1999; Lill et al. 1999; Beinert 2000; Lill and Kispal 2000; 
Muhlenhoff and Lill 2000).  
Cytosolic aconitase is an interesting example of the FeS cluster proteins 
having sensing and regulatory functions. Mitochondrial aconitase, containing a FeS 
cluster, is an enzyme of the citric acid cycle, catalyzing the isomerization of citrate 
to isocitrate through steps of dehydration and hydration. Cytosolic aconitase, which 
shares a 30% amino acid homology with its mitochondrial counterpart, also 
contains an FeS cluster, but the cluster is relatively unstable, dissociating from the 
apoprotein in low-iron conditions. This change in conformation makes cytosolic 
aconitase an iron-response element -binding protein (IRE-BP).The IRE-BPs bind to 
the iron-responsive elements (IRE) of the 5’UTR of the ferritin mRNA, blocking 
the translation of this iron-storage protein. They also bind to the IREs in the 3’UTR 
of the transferrin receptor mRNA. This stabilizes the mRNA, leading to increased 
translation of the transferrin receptor, the protein responsible for iron uptake by the 
cells. The conformation change is reversible, and, in high-iron conditions, the IRE-
BP again binds an FeS cluster, being thereafter unable to bind IREs. (Berg et al. 
2001a; Walker et al. 2001). 
Some ten mitochondrial proteins involved in the FeS cluster assembly 
machinery have been identified in yeast so far. These proteins share homologies 
with bacterial proteins performing the same task. Presumably, FeS proteins 
occurred early in evolution, and are present in the cells of virtually all species. 
Interestingly, synthesis of FeS proteins seems to be a more vital function of the 
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mitochondria than oxidative phosphorylation. The yeast strains with defects in the 
proteins involving the function of the respiratory chain usually have a petit 
phenotype – they grow on glucose using anaerobic metabolism and forming small 
colonies, but cannot grow on glycerol, since on non-fermentable carbon sources the 
yeast cells depend on aerobic metabolism. Yeast strains deleted for NFS1, YAH1, 
JAC1 or ARH1, four essential genes involved in FeS cluster formation, cannot 
grow at all. (Lill et al. 1999; Lill and Kispal 2000; Muhlenhoff and Lill 2000). 
ABCB7 and ABCB6, the human orthologs of yeast Atm1p 
Mitochondria are needed not only for synthesis of the mitochondrial FeS 
proteins, but also for maturation of the extramitochondrial ones. The details of the 
formation of the cytosolic FeS proteins are not known yet, but the FeS clusters are 
probably formed in the mitochondria and transported to the cytosol, where they are 
incorporated to the apoproteins (Muhlenhoff and Lill 2000). Yeast protein Atm1p 
is a mitochondrial yeast protein presumably exporting FeS clusters from the 
mitochondria. Defects in the Atm1p result in defective assembly of cytosolic FeS 
proteins, deficiency of the holoforms but not of the apoforms of heme-bearing 
proteins, accumulation of iron in mitochondria, the instability of the mitochondrial 
DNA and the loss of oxidative respiration function (Leighton and Schatz 1995; 
Kispal et al. 1997; Kispal et al. 1999; Senbongi et al. 1999). Atm1p belongs to the 
protein superfamily of the ATP binding cassette (ABC) transporters, and has two 
human orthologs, ABCB7 and ABCB6 (Lill and Kispal 2001). (ABCB7 and 
ABCB6 are the systematic names of these proteins and the corresponding genes. 
Previously, ABCB7 was called ABC7 or hABC7, and the previous name of 
ABCB6 was MTABC3.) Both human genes, ABCB7 and ABCB6, are able to 
partially reverse the phenotype of the yeast strains with Atm1p defects (Allikmets 
et al. 1999; Mitsuhashi et al. 2000). 
ABCB7 has been mapped to the X-chromosome (Savary et al. 1997; 
Shimada et al. 1998). Missense mutation I400M in ABCB7 results in X-linked 
sideroblastic anemia with ataxia (OMIM 301310), a recessive disorder 
characterized by in early childhood onset of non-progressive cerebellar ataxia and 
mild anemia with hypochromia and microcytosis (Allikmets et al. 1999). The 
disease causes iron accumulation in the mitochondria, but its pathogenesis is not 
yet well understood. 
ABCB6 has been mapped to chromosome 2, and so far no human 
diseases associated with mutations in it have been reported. ABCB6 has, however, 
been advocated in the literature as the gene most probably affected in the 
GRACILE syndrome (Mitsuhashi et al. 2000; Lill and Kispal 2001). 
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Other diseases with abnormalities of mitochondrial iron metabolism 
Mitochondria play a central role in cellular iron metabolism. They are 
the site of several steps of heme biosynthesis, and contain large amounts of non-
heme iron in the FeS clusters of the electron transport chain. However, in addition 
to X-linked sideroblastic anemia with ataxia, only two Mendelian disorders are 
known to be associated with impaired iron homestasis in mitochondria: X-linked 
sideroblastic anemia (OMIM 301300) and Friedreich ataxia (OMIM 229300). 
X-linked sideroblastic anemia is caused by mutations in the gene 
encoding delta-aminolevulinate synthase 2, ALAS2 (previous symbols ALAS,
ALASH, e-ALAS) (Cox et al. 1994). ALAS2 carries out the first step of heme 
biosynthesis, catalyzing the condensation of glycine and succinyl coenzyme A to 
produce aminolevulinic acid (ALA). When heme biosynthesis is stalled by 
deficiency of ALAS2, iron accumulates in the mitochondria, resulting in a 
characteristic picture of ringed sideroblasts in the erythroid marrow. The anemia is 
usually normocytic and normochromic, but it may be microcytic and hypochromic, 
i.e. similar to other anemias that result from insufficient hemoglobin production. 
Many patients respond to pyridoxine, a cofactor of ALAS2. (Andrews 2000). 
Friedreich ataxia is an autosomal recessive disorder characterized by 
spinocerebellar degeneration, cardiomyopathy and diabetes mellitus. The 
symptoms begin in childhood, and the disease leads to death in the fourth or fifth 
decade of life. Friedreich ataxia is caused by mutations in the frataxin gene, FRDA
(other symbol X25) (Campuzano et al. 1996), the majority of the mutations being 
GAA-triplet repeat expansions in the first intron of the gene. Frataxin is a 
mitochondrial protein, the gene encoding it being located on chromosome 9q13. 
Decreased frataxin leads to accumulation of mitochondrial iron with failure of 
mitochondrial respiratory function. The yeast cells deleted for YFH1 gene, the 
yeast homolog of frataxin, also accumulate iron in their mitochondria. Drastic 
increases in the concentrations of mitochondrial free iron have been reported upon 
inactivation of several yeast genes involved in the FeS cluster assembly. YFH1 and 
frataxin might also play a role in FeS cluster formation, but their precise function is 
so far unknown. (Muhlenhoff and Lill 2000; Becker and Richardson 2001; Patel 
and Isaya 2001). 
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AIMS OF THE STUDY
This work was undertaken when the GRACILE syndrome had been newly 
discovered. The clinical characteristics of this fatal metabolic disorder were 
defined and the autosomal recessive inheritance was established, but the 
pathogenesis of the disease remained unknown. The aim of this study was to 
elucidate the molecular genetic background of the GRACILE syndrome, with the 
following specific aims: 
1) To assign the GRACILE locus,  
2) To restrict the critical chromosomal region, 
3) To identify the causative gene either by positional cloning or by the 
positional candidate approach,  
4) To provide functional evidence for the causative role of the identified 
mutation, and 
5) From the clinical point of view, to produce DNA diagnostics for the 
GRACILE syndrome. 
39
SUBJECTS AND METHODS 
GRACILE families and patient samples 
DNA samples from 19 Finnish GRACILE patients, 22 parents, 13 
siblings and three half-siblings from 13 families were used for linkage and 
sequence analyses. Autopsy samples, muscle biopsy specimens or fibroblast cell 
lines of nine patients were used for RNA extractions and activity measurements of 
the mitochondrial enzyme complexes. In addition, DNA samples from three British 
infants (Morris et al. 1995) with a disease picture closely resembling that of the 
Finnish GRACILE patients were used for sequencing studies. This study was 
approved by the Ethical Committee of the Hospital for Children and Adolescents, 
Helsinki University Central Hospital, Finland, and parental informed consent was 
obtained.
Control samples 
As controls for the linkage disequilibrium analyses, DNA samples of 46 
individuals originating from eastern and central Finland were used. As controls in 
mutation screening we used 494 Finnish individuals, 70% of them originating from 
eastern and central Finland, and a control panel of 50 Caucasian individuals 
(HD50CAU, Coriell Cell Repositories). This control panel consisted of 50 
Americans originating from different parts of Europe. 
Control liver tissue samples used for RNA extraction were derived from 
two adults who had died in accidents, and the control fibroblast cell line used as an 
RNA control was also adult-derived. 
DNA and RNA extraction 
Genomic DNA of the deceased patients was extracted either from 
cultured fibroblasts using standard procedures, or from paraffin-embedded tissue 
samples by the rapid lysis method (Isola et al. 1994). DNA of the living patients 
and healthy family members was extracted from 2-20 ml peripheral blood samples 
according to standard procedures.  
For RT-PCR sequencing, total RNA was extracted from deep frozen 
liver and kidney tissue samples, using the RNeasy Mini Kit (QIAGEN). Messenger 
RNAs for Northern blot analysis were extracted from fibroblast cell lines and liver 
tissue samples, using the Oligotex mRNA Direct Mini kit (QIAGEN). 
Genotyping
A slightly modified Weber screening set (Sheffield et al. 1995) of 380 
polymorphic microsatellite markers was used in the genome screen. The markers 
were amplified by PCR, and the PCR products were separated on an automated 
40
laser fluorescence DNA sequencer (ALF Express, Pharmacia, Sweden). The 
microsatellite markers used in the dense mapping of the GRACILE locus 
originated from several internet databases. The primers were labeled with 32P, and 
the PCR reactions and the size analysis of the PCR products were performed as 
described earlier (Aaltonen et al. 1993). Later, the exact allele sizes of the critical 
markers were determined using fluorescently labeled PCR primers, ABI377 
sequencer and GENOTYPER program, version 2.0 (Applied Biosystems). 
Microsatellite genotyping for diagnostic purposes was performed with this system. 
The SNP markers flanking ABCB6 were genotyped by direct sequencing. 
Linkage and LD analyses 
The principle of linkage analysis is to assign a disease locus to a specific 
chromosomal region by comparing the segregation of the alleles of genetic markers 
in families with affected individuals. If two loci (the marker and the disease locus) 
co-segregate in the pedigrees more often than they would by chance, they are said 
to be linked, meaning that they lie very close to each other in a chromosome. In 
practice, if the disease is inherited by autosomal recessive inheritance, a genetic 
marker is linked to the disease if affected siblings always inherit the same marker 
alleles from both parents, but the healthy siblings carry only one, or none, of these 
alleles. The unit for genetic distances is a centimorgan (cM), which corresponds to 
a recombination fraction of 1%, and implies that two loci 1 cM apart have 
approximately a 1% chance of recombination during meiosis. If the study sample is 
small, a marker can also seem linked by chance. The statistical significance of 
linkage is expressed by LOD (logarithm of odds) score. In linkage analysis two 
assumptions are tested: 1) the two loci are linked with a given recombination 
fraction (?), or 2) they are not linked. The ratio of these likelihoods is called a 
likelihood ratio, and LOD score is the log10 of this ratio (Ott 1974; Terwilliger and 
Ott 1994). Thus a LOD score of 3.0 means roughly that it is 1000 times more likely 
that two loci are linked than that the observed allele segregation in the families 
would have arisen by chance. A LOD score around zero means that the marker is 
non-informative, or that the study sample is too small, and LOD scores under -2 
indicate exclusion of the locus as the disease locus.
Two-point linkage analyses in this study were carried out with the 
MLINK option of the LINKAGE package computer programs, version FASTLINK 
2.2 (Lathorp and Lalouel 1984), assuming autosomal recessive inheritance, 
complete penetrance and no phenocopies. The consanguinity of the parents of 
family 1 was taken into account in the linkage analyses.  
The principle of LD is discussed in the review of the literature. Two-
point linkage disequilibrium analyses of this study were carried out with the 
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DISLAMB computer program, and multipoint linkage disequilibrium analysis was 
performed with the DISMULT computer program (Terwilliger 1995).  
Radiation hybrid mapping
The order and approximate distances of the genetic markers in the 
critical GRACILE region were determined by radiation hybrid (RH) mapping. This 
is a method based on cell hybrid panels created by fusing rodent and X-ray-treated 
human cells. A high dose of X-rays is used to fragment the human genomic DNA, 
and the broken chromosomal fragments are rescued by cell fusion with a recipient 
rodent cell line. A panel of individual fusion cell lines can then be analyzed for the 
presence or absence of different markers by PCR. Markers located very close to 
each other will be positive for the same, or almost the same, cell lines, since within 
a short distance the X-rays do not break the DNA many times. The markers can be 
ordered, and the physical distance separating them estimated, by statistical 
analyses. (Goss and Harris 1975; Cox et al. 1990; Boehnke et al. 1991).  
In this study, we used Stanford medium(G3) and high(TNG) resolution 
RH panels. The markers were amplified by PCR and the products were separated 
by electrophoresis on agarose gels. 
The RH mapping data were analyzed using the FORTRAN program 
RHMAXLIK of the RHMAP package version 3.0 (Lange et al. 1995; Lunetta et al. 
1996). This program orders the markers and calculates marker distances in 
centirays (cR). It allows the use of data from several RH panels simultaneously, 
which was important in this study, because the ordered markers were too close to 
each other to be ordered with the Stanford G3 RH panel only, and too distant from 
each other to be ordered with the Stanford TNG RH panel alone. We used the data 
of both these panels and the branch and bound ordering option to determine the 
order and distances of the critical markers. The marker distances were converted 
from cR to cM by dividing the known total length (in cM) of the linked region 
proportional to the marker distances in cR.
Bioinformatics 
The sequence databases and various programs for data processing 
provided on the web pages of different universities and organizations are essential 
tools in molecular genetics. The detailed web addresses of the internet databases 
mentioned here are provided in the electronic database information section. 
For the fine mapping of the GRACILE region (carried out in 1997-
1998), we utilized the marker maps of Genethon, the University of Southampton 
(Genetic location database, LDB), Whitehead Institute and Genome Database 
(GDB). The Stanford RH-panel raw data, available for some of the critical markers 
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on the Stanford Human Genome Center web pages, were utilized when the markers 
were arranged by RH-mapping.  
“A new gene map of the human genome” at NCBI’s web page, 
containing EST:s, mRNA:s and genes organized by RH mapping (Deloukas et al. 
1998), was our first tool in searching for good positional candidate genes within the 
critical GRACILE region. The amount of the draft genomic sequence in the critical 
region, available in GenBank, increased exponentially in 1999-2000. While 
analyzing the positional candidate genes, we followed the development of the 
NCBI’s “Map Viewer” and the “Human genome project working draft” of UCSC, 
updating new possible candidate genes and useful genetic markers. These are 
human genome assemblies providing locations of the markers and genes based on 
the actual sequence, but also providing links with the earlier physical and genetic 
maps.
In order to define the exact position of the ABCB6 gene, we built 
physical maps in silico. The sequences of the genomic clones were searched at 
nucleotide and htgs (high throughput genomic sequence) databases with critical 
markers using BLAST programs (Altschul et al. 1990) at NCBI. New markers in 
the genomic clones were found by running electronic PCR (Schuler 1997) at 
NCBI. The sequence utilities of the Search Launcher at the web pages of Baylor 
College of Medicine, as well as the commercial SEQUENCHER computer 
program provided practical tools for the handling of the DNA sequences. 
The genomic structure of the BCS1L gene was also determined using 
biocomputing tools. The genomic clone containing BCS1L was identified by a 
BLAST search with the BCS1L mRNA sequence. In order to find all the different 
splice variants of the gene we searched the human EST and nucleotide databases 
with the coding part of the BCS1L mRNA using BLAST programs. The different 
EST and mRNA sequences were then aligned with the genomic clone and divided 
into exons so that all the exon-intron boundaries followed the GT-AG rule (Mount 
1982).
BLAST programs and protein sequence databanks at NCBI, as well as 
the MultAlin alignment program (Corpet 1988), were used to define the functional 
domains and conserved regions of the human BCS1L, by comparing the protein 
sequence with those of other organisms. 
   
Sequencing and mutation screening 
RT-PCR and genomic sequencing of the candidate genes were performed 
using BigDye terminator kit and ABI 377 and ABI 3700 automated sequencers 
(Applied Biosystems). The sequences were analyzed by the SEQUENCHER 
program.  
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Screening of the 232A>G (S78G) point mutation in the BCS1L gene in 
the Finnish GRACILE patients and their parents was carried out by direct 
sequencing. Mutation screening in siblings and control samples was performed 
using solid-phase minisequencing (Syvänen et al. 1993). For other mutations, the 
controls were screened by direct sequencing. 
Northern blot analysis 
Northern blotting was performed using standard procedures. Probes for 
ABCB6 and BCS1L were produced by RT-PCR and labeled with 32P, using a 
random primer DNA labeling system (Life Technologies). Hybridizations were 
carried out in Expresshyb hybridization solution (Clontech) as suggested by the 
manufacturer.
Expression plasmid construction, cell culture, and transfections 
BCS1L cDNA with a c-terminal FLAG sequence was PCR-cloned to a 
pGEM®-T Easy vector (Promega). 232A>G (S78G) mutagenesis was carried out in 
pGEM-T Easy vector, using the QuickChange site-directed mutagenesis kit 
(Stratagene). Wild-type and mutant BCS1L cDNAs were then subcloned to the 
pCMV5 expression vector (Andersson et al. 1989). COS-1 cells obtained from the 
American Type Culture Collection were transiently transfected with the cDNA 
constructs, using Lipofectamine and PLUS reagent (Life Technologies), following 
the manufacturer’s guidelines. 
Immunofluorescence microscopy 
For immunonofluorescence microscopy, COS-1 cells were plated on 
cover slips and transfected as described above. 48 h after transfection, the cells 
were incubated in DMEM without FBS, in the presence of 50 ?g/ml of 
cycloheximide, for one hour to halt protein synthesis, and for an additional 30 
minutes with cycloheximide and 200 nM MitoTracker Red CMXRos (Molecular 
Probes) for mitochondrial staining. Thereafter, the cells were fixed with methanol, 
blocked with 0.5% BSA/0.2% saponin, and incubated with anti-FLAG M2 
antibody (Stratagene). The cells were washed with 0.5% BSA/0.2% saponin and 
stained with FITC-conjugated anti-mouse secondary antibody (Sigma). After 
washing with PBS, the cells were mounted in glycerol and viewed with an 
immunofluorescence microscope.  
Western blot analysis 
For Western blot analysis, COS-1 cells were lysed 48 h after transfection 
with lysis buffer supplemented with protease inhibitors. Samples were denatured 
and electrophoresed on a 10% SDS-PAGE gel. Western blotting was performed 
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according to standard procedures. The membrane was stained with anti-FLAG M2 
antibody (Stratagene), the secondary antibody being peroxidase-conjugated anti-
mouse IgG (Sigma). The signals were detected using ECLTM Western blotting 
detection reagents (Amersham Pharmacia Biotech). 
Pulse chase analysis 
The half lives of the wild-type and S78G mutant BCS1L polypeptides 
were determined by pulse chase experiments. Cells were labeled metabolically 36 h 
after transfection by starving them in methionine- and cysteine-free medium for 
one hour and thereafter labeling with both [35S]methionine and [35S]cysteine for 
one hour. Then the cells were incubated for 0, 12, 24, 36 or 48 h in chase media 
and lysed with lysis buffer supplemented with protease inhibitors. The lysed cells 
were immunoprecipitated with anti-FLAG M2 antibody (Stratagene) and Protein 
A/G Sepharose (Santa Cruz Biotechnology). Immunocomplexes were separated on 
10% SDS-PAGE and visualized by fluorography. The results were analyzed by
densitometry.  
Yeast complementation studies 
Human BCS1L cDNA, 480bp of yeast BCS1 upstream sequence, and 
210bp of yeast BCS1 downstream sequence were PCR-cloned to the pBluescript®
(Stratagene) vector. 232A>G (S78G) mutagenesis in BCS1L cDNA was carried 
out, using the QuickChange site-directed mutagenesis kit (Stratagene). The whole 
cassette containing yeast BCS1 promoter, human BCS1L cDNA and yeast BCS1
terminator was then subcloned to the high-copy yeast expression vector pRS425 
(Sikorski and Hieter 1989). Yeast strain Y14211 (EUROSCARF, European 
Saccharomyces cerevisiae archives for functional analysis), deleted for BCS1, was 
transformed with the constructs. Transformations were performed by the lithium 
acetate procedure (Ito et al. 1983). Individual transformants were purified and 
checked for growth on YPEG plates (3% glycerol, 2% ethanol, 2% peptone, 1% 
yeast extract and 2% agar). To control the growth on glucose, the same 
transformants were also streaked on YPD plates (2% glucose, 2% peptone, 1% 
yeast extract and 2% agar), and on SD plates without leucine (2% glucose, 0.67% 
yeast nitrogen base, 2% agar, 20µg/ml histidine, uracil and tryptophan, and 
30µg/ml adenine and lysine). 
Activity measurements of mitochondrial enzyme complexes  
Mitochondria were isolated from muscle biopsy specimens of five 
Finnish GRACILE patients, and from several autopsy-derived tissues obtained 
from four patients 2-7 h post mortem. The activities of respiratory chain enzymes 
(NADH:cytochrome c oxidoreductase (complex I + III), succinate:cytochrome c
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oxidoreductase (complex II + III), succinate:ubiquinone oxidoreductase (complex 
II) and cytochrome c oxidase (complex IV)) were measured spectrophotometrically 
(Majander et al. 1995). The measurements were performed at the Department of 
Medical Chemistry of the University of Helsinki in Helsinki, Finland. A modified 
spectrophotometric assay (Rustin et al. 1994) including separate assessment of 
NADH:ubiquinone oxidoreductase (complex I) and ubiquinol:ferricytochrome-c
oxidoreductase (complex III) was used to measure the enzyme activities from three 
deep-frozen liver samples and one muscle sample of the patients. These 
measurements were carried out at the Department of Pediatrics (Division of 
Pediatric Neurology and Metabolism) of the Ghent University Hospital in Ghent, 
Belgium.  
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RESULTS AND DISCUSSION 
Assignment of the GRACILE locus to chromosome 2 (I) 
The GRACILE locus was initially mapped by genome scan and linkage 
analysis, and the locus was confirmed and restricted by LD and haplotype analyses, 
using 11 markers ordered by RH mapping. We had DNA samples available from 
eight nuclear families, only four of which had two affected children (figure 5). In 
addition, DNA samples from two affected individuals from different families were 
used. These two samples were included in the LD analyses, but provided no 
information on linkage analysis. The parents of family 1 were second cousins, and 
based on genealogical studies the mother of family 4 and the father of family 5 
were probably distant relatives. This number of families is not sufficient for disease 
locus assignment by conventional linkage analysis. However, since the GRACILE 
syndrome shows an autosomal recessive mode of inheritance, and the birthplaces 
of the families’ ancestors were distributed in the late-settlement region of Finland, 
we assumed that all the families, or most of them, probably had a common ancestor 
and carried the same founder mutation. Therefore, we expected to be able to utilize 
LD and ancestral haplotype analyses for disease gene localization.  
Genome screen and linkage analysis 
 The initial genome screen was carried out using DNA samples from 
only nine individuals: four affected sib pairs and the affected infant of family 5 
(indicated by asterisks in figure 5). The affected infant of family 5 was included 
because the mother of family 4 and the father of family 5 were believed to be 
related, and consequently they may have shared a long chromosomal segment 
around the disease locus. The parents of family 1 were second cousins, and we 
assumed that the affected sibs in this family would be homozygous for the markers 
flanking the GRACILE locus. The analysis of the genotypes in the initial genome 
scan was carried out in a very simple and rapid way, by comparing the genotypes 
of the sibs within each family and looking for markers showing identical genotypes 
in sib pairs. After analyzing only 25 markers of the genome scan panel, we found 
two adjacent markers on chromosome 2q, D1S1649 (which, despite its name, maps 
to chr. 2) and D2S434, 5 cM apart, revealing identical genotypes in each of four sib 
pairs. In addition, marker D2S1363, 14 cM apart from marker D2S434, revealed 
identical genotypes in three sib pairs. In family 1, whose parents were second 
cousins, the sibs were homozygous for all these three markers. These markers were 
then genotyped in the complete family material. No obligatory recombinations 
could be identified between marker D2S434 and the GRACILE phenotype, the 
maximun LOD score being 3.0 at recombination fraction (?) 0. 
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Figure 5 
GRACILE pedigrees used in the linkage and LD studies (I). Asterisks indicate individuals 
whose DNA samples were analyzed in the initial genome screen. 
The next step was to analyze several markers around marker D2S434 on 
chromosome 2q33-37 in the complete family material. Multiple markers between 
markers D2S164 and D2S2359 provided positive LOD scores (max. lod scores 
0.91-3.88 at ?=0), suggesting a linkage on a 3 cM region (table 4). In the 
constructed haplotypes of the families, no obligatory recombination events could 
be detected between the GRACILE phenotype and a total of 11 markers on this 3 
cM region. The affected infants of family 1 were homozygotes for all the markers 
over this region. 
LD  analyses and RH mapping of the critical region
To confirm the linkage and to restrict the critical chromosomal region, 
we performed LD analyses with all the markers that provided maximum two-point 
lod scores at recombination fraction 0. Since we had only 20 affected and 16 
nonaffected chromosomes in our family material, we obtained additional non-
affected chromosomes from regionally selected control samples. In total, we 
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Table 4 
Pairwise linkage and LD analyses between the GRACILE syndrome and 15 marker loci in 
2q33-37. Linkage analysis was carried out in eight families, and LD calculations were 
performed using allele data of 20 GRACILE and 108 control chromosomes. 
Marker Two-point linkage analysis, 
LOD Score at ?=0 
Two-point LD 
analysis, p value 
D2S301 - ? - 
D2S164 - ? - 
D2S2210 2.09 0.4 
D2S434 3.00 0.05 
D2S2249 3.57 0.002 
D2S173 2.33 0.06 
D2S104 2.63 0.002 
D2S2179 2.16 0.002 
D2S2250 3.88 1 x 10-12
D2S433 2.29 2 x 10-9
D2S1354 0.91 0.0003 
D2S2244 2.54 5 x 10-7
D2S163 3.30 0.005 
D2S2359 - ? - 
D2S120 - ? - 
utilized 20 GRACILE and 108 control chromosomes in the linkage disequilibrium 
studies.
The p values of the LD analyses for each of the 11 markers on the 
linkage region on 2q33-37 are presented in table 4 (detailed results in I). Marker 
D2S2250 showed the most significant LD; all the GRACILE chromosomes carried 
the same allele 4, the proportion of which in the nondisease chromosomes was 21% 
(p value 10-12). This confirmed the assignment of the GRACILE locus to the 
vicinity of this marker. Markers D2S433 and D2S2244 also provided significant p 
values in the LD analysis, and several flanking markers showed suggestive, 
although not significant, evidence of LD. 
To be able to carry out multipoint LD analysis and to build the ancestral 
haplotypes correctly, we performed radiation hybrid mapping of the critical 
markers to confirm their order. The 11 linked markers were too close to each other 
to be ordered with the medium-resolution RH panel, but the distance between 
markers D2S2179 and D2S2250 turned out to be so long that not all the markers 
were linked in the high-resolution RH panel. We typed the markers in both panels 
and performed the RH data analysis with a computer program allowing the use of 
data from the two panels simultaneously. The most probable marker order and the 
approximate marker distances on the basis of this analysis are shown in figure 6A. 
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The total map length from D2S2210 to D2S163 was 60 cR10 000. Since 1 cR10 000 
corresponds on average to 25 kb (Lunetta et al. 1996), the physical length of the 3 
cM linkage region was estimated to be approximately 1.5 Mb, and that of the most 
critical 1 cM to be approximately 500 kb. 
The multipoint LD analysis carried out with these markers resulted in a 
maximum lod score of 30.9 in the immediate vicinity of marker D2S2250 (figure 
6A).
Haplotype analysis
The haplotypes of the GRACILE chromosomes are shown in table 5. 
The haplotypes of families 1-8 are presented as paternal and maternal disease 
chromosomes. In families 9 and 10 the parental data were missing, and 
consequently only the genotypes of the affected infants are shown. For these cases, 
we constructed the haplotypes on the basis of the expected common ancestors with 
the other affected individuals. 
The 1 cM core haplotype cen-1-2-4-2-3-tel (D2S104-D2S2179-
D2S2250-D2S433-D2S1354) was observed in 18/20 of the disease chromosomes. 
One of the haplotypes differing from the core haplotype had different alleles with 
markers D2S104 and D2S2179 and the other had a different allele with marker 
D2S433. The causative gene is probably located very close to the marker D2S2250, 
since all the GRACILE chromosomes carried the same allele 4, which was present 
in 21% of the control chromosomes, with this marker. In addition, with marker 
D2S1354, all the GRACILE chromosomes carried the same allele 3, but this allele 
was also very common (71%) in the control chromosomes. On the centromeric side 
of marker D2S2250, the critical DNA region was distinctly restricted by marker 
D2S2179, since the affected chromosome of the mother of family 4 was entirely 
different from the conserved GRACILE haplotype with marker D2S2179 and the 
markers centromeric from it. On the telomeric side of marker D2S2250, the border 
of the critical chromosomal region remained less definitive. With marker D2S433, 
the infant of family 10 was heterozygous for the core haplotype alleles 2 and 3. 
However, allele 3 differed from allele 2 by one tetranucleotide repeat only, and 
thus a marker mutation could not be excluded, especially since, with marker 
D2S2244, this infant was homozygous for allele 1, which showed strong linkage 
disequilibrium with the disease. Therefore the critical GRACILE region was not 
definitely restricted by marker D2S433, but lay between markers D2S2179 and 
D2S2244. Most probably, the causative gene was located in the immediate vicinity 
of marker D2S2250. 
The length of the shared haplotype was comparable to that observed in 
infantile-onset spinocerebellar ataxia (IOSCA), another Finnish disease occurring 
mostly in the late-settlement region of eastern and central Finland (Varilo et al. 
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1996). This was in accordance with the results of the genealogical studies, 
suggesting that the GRACILE mutation was probably introduced into the Finnish 
population some 30-40 generations ago and spread to the late-settlement region 
with the population migration of the 16th century.  
The mapping strategy and the importance of LD
In the initial genome screening, we used DNA samples from only nine 
individuals. This efficient screening method has previously been used successfully 
in the identification of other monogenic disease loci of the Finnish disease heritage 
(Mäkelä-Bengs et al. 1998; Pekkarinen et al. 1998). As in these earlier studies, we 
did not find a conserved haplotype shared by all affected individuals with the 
marker density utilized in the first stage of the genome scan, although a common 
ancestor in the distant past was suspected. However, it proved successful to 
monitor for shared genotypes between siblings within each family. If the families 
have common ancestors only a few generations back, a genome scan can be carried 
out very efficiently by monitoring for chromosomal regions, in which the affected 
individuals show homozygosity for genetic markers (homozygosity mapping) 
(Lander and Botstein 1987; Houwen et al. 1994; Nikali et al. 1995). This principle 
was also demonstrated in this study by family 1, in which the parents were second 
cousins, and the affected infants showed homozygosity of the genetic markers over 
a long chromosomal region. However, usually the chromosomal segments that are 
shared by most of the individuals carrying one founder mutation, are very short, 
and “pure” homozygosity mapping cannot be applied at the first stage of a genome 
scan. This is true among the diseases belonging to the Finnish disease heritage also. 
The conserved haplotypes of the disease alleles in patients from different nuclear 
families are very short (usually 0.5-2cM), although many of the founder mutations 
are relatively young (de la Chapelle and Wright 1998; Peltonen et al. 1999).  
LD and ancestral haplotype analyses have facilitated all positional 
cloning projects of the Finnish disease heritage by allowing further restriction of 
the critical chromosomal region after conventional linkage analysis. In this study 
also, the linkage disequilibrium and ancestral haplotype analyses restricted the 
critical chromosomal region from the initial 3 cM to 1 cM. Even more importantly, 
these methods made locus assignment possible despite such a small number of 
families. The two-point lod scores 0.91-3.88 obtained with conventional linkage 
analysis were suggestive, but the p value of 10-12 with marker D2S2250 in the LD 
analysis, the lod score 30.9 in the multipoint LD analysis and the finding of the 
conserved haplotype in the GRACILE chromosomes unequivocally confirmed the 
locus assignment.
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Table 5 
Haplotypes of the GRACILE chromosomes in the 3 cM linkage region. Shading indicates 
the shared core haplotype. 
Family D
2S
22
10
D
2S
43
4
D
2S
22
49
D
2S
17
3
D
2S
10
4
D
2S
21
79
D
2S
22
50
D
2S
43
3
D
2S
13
54
D
2S
22
44
D
2S
16
3
1 P 2 4 4 2 1 2 4 2 3 1 6
1 M 2 4 4 2 1 2 4 2 3 1 6
2 P 3 2 2 3 1 2 4 2 3 2 6 
2 M 1 3 2 5 1 2 4 2 3 1 4 
3 P 3 2 2 3 1 2 4 2 3 1 6
3 M 3 4 2 3 1 2 4 2 3 2 6 
4 P 3 2 2 3 1 2 4 2 3 1 6
4 M 1 4 5 1 2 3 4 2 3 2 5 
5 P 3 2 2 3 1 2 4 2 3 1 1 
5 M 3 4 4 3 1 2 4 2 3 1 4 
6 P 2 4 4 2 1 2 4 2 3 1 3 
6 M 2 2 2 3 1 2 4 2 3 2 6 
7 P 2 4 4 2 1 2 4 2 3 1 5 
7 M 3 2 2 3 1 2 4 2 3 1 6
8 P 3 2 2 3 1 2 4 2 3 2 6 
8 M 3 3 2 3 1 2 4 2 3 2 6 
9 O 1 5 2 3 1 2 4 2 3 2 2 
9 O 2 4 4 2 1 2 4 2 3 1 3 
10 O 3 2 5 3 1 2 4 2 3 1 6
10 O 2 4 4 2 1 2 4 3 3 1 4 
Analysis of the positional candidate genes ABCB6 and BCS1L (III, IV)
Genes in the critical GRACILE region 
The critical GRACILE region, restricted by haplotype analysis, reached 
from D2S2179 to D2S2244. When the linkage was found, the length of this 
chromosomal region was estimated to be 1-1.5 cM and about 500-700 kb, based on 
rough genetic maps and RH mapping. At that time the Human Gene Map at 
NCBI’s web page provided four cloned genes and 20 mapped EST:s on the 4 cM 
interval (D2S164-D2S163) including the critical GRACILE region. Now the 
genomic sequence of the critical region is almost complete, and in the NCBI’s 
latest human genome assembly (MapViewer in August 2002), the physical interval 
is 1.3 Mb. It contains almost 30 known genes and several predicted, hypothetical 
52
genes, representing a gene-rich region. Figure 6A shows the RH mapping -based 
marker map of the critical region four years ago, and figure 6B shows the present 
situation. The critical chromosomal interval contains two interesting candidate 
genes, ABCB6 and BCS1L, both encoding mitochondrial proteins.   
RH mapping with the Stanford medium resolution RH panel G3 
localized the BCS1L to the immediate vicinity of the markers D2S2250 and 
D2S433, and ABCB6 between markers D2S433 and D2S2244. In addition, 
ABCB6 hit the same BAC clone, RP11-747C8, as D2S2244, implying that the 
gene was located closer to D2S2244 than to D2S433. During the sequencing of 
chromosome 2 (by HGP), these conclusions about the locations of ABCB6 and 
BCS1L turned out to be correct. Thus BCS1L was located in the middle of the 
critical GRACILE region, whereas ABCB6 lay on the very edge of it, being 
positionally not the most likely candidate, though theoretically possible. However, 
functionally ABCB6 was exceptionally interesting. It was known to be involved in 
iron homeostasis, mitochondrial respiratory function and maintenance of the 
stability of mitochondrial DNA, and ABCB6 had even been advocated in the 
literature as the most probable candidate gene for the GRACILE syndrome 
(Mitsuhashi et al. 2000; Lill and Kispal 2001). In contrast, BCS1L was functionally 
only a moderate candidate. It encoded a mitochondrial protein, whose yeast 
homolog Bsc1p was known to be essential for the function of the mitochondrial 
respiratory chain complex III. The symptoms of the GRACILE patients might be 
caused by a mitochondrial defect, but the activities of the respiratory chain 
complexes in the GRACILE patients had been shown to be within the normal 
range. We therefore analyzed both of these interesting candidates. 
Sequence analysis of ABCB6 and BCS1L  
We searched for ABCB6 mutations in the patients’ DNA samples by 
sequencing the coding region of the gene. In addition, 1300 bp of the genomic 
sequence upstream from the start codon and 500 bp of the genomic sequence 
downstream from the stop codon (including 5’ and 3’ UTRs) were sequenced. 
There were no possible mutations in these regions of the ABCB6 in the patients, as 
compared with the controls and the reference sequences, but an SNP was identified 
in one patient. He had a heterozygous A>G nucleotide change, 218bp downstream 
from the stop codon, and 52bp downstream from the last base of exon 19.  
The sequencing of the BCS1L covered the whole genomic sequence, 
including 2020 bp of the upstream, and 1040 bp of the downstream sequence. All 
the Finnish GRACILE patients had a homozygous 232A>G nucleotide change, 
causing an S78G amino acid change, in the second exon of BCS1L. All the parents 
were heterozygous for this variation, and the siblings and half-siblings of the 
patients were either homozygous for the normal allele, or heterozygous. There 
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Figure 6 
A) Multipoint LD analysis of 11 markers in the 3 cM linkage region with 20 disease and 
108 nondisease chromosomes. The marker order and distances are based on the RH 
mapping performed in 1998 (I). B) The order and distances between the critical markers 
and the analyzed positional candidate genes, BCS1L and ABCB6, as they were in the 
NCBI’s Map viewer in August 2002.  
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were no other nucleotide changes in the BCS1L sequence in the patients. Of the 
494 control Finns and 50 other Caucasians screened for the 232A>G nucleotide 
change, one Finnish control was a heterozygote, and all the other controls were 
homozygous for the normal allele. 
Northern blot analysis of ABCB6 and BCS1L  
Northern blot analyses of ABCB6 and BCS1L were carried out in Finnish 
GRACILE patients to monitor the steady-state expression level of the genes and 
any possible differences in the transcript sizes. Hybridizations of both the ABCB6
and BCS1L probes were carried out using fibroblast mRNA filters, and the BCS1L
probe was also hybridized with a liver filter. No differences in the steady-state 
expression levels or transcript sizes were detected between the GRACILE patients 
and the controls with either of these genes (figures in III and IV). 
Positional exclusion of ABCB6  
Since all the Finnish GRACILE families carried the same ancestral 
haplotype, the patients should be homozygous for the disease mutation and the 
genetic markers in its immediate vicinity. Thus, the heterozygous nucleotide 
variant found 218 bp downstream from the stop codon of ABCB6 in one patient 
suggested that ABCB6 could also be positionally excluded. To confirm the 
exclusion of ABCB6, we monitored for this SNP in the whole study sample of ten 
families. We also screened for other SNPs and found another informative SNP 
(NCBI ss# 12967), located 1543 bp upstream from the start codon of ABCB6. This 
SNP was also genotyped in all the families, and haplotypes were constructed using 
the genotype data of both sequenced SNPs and flanking microsatellite markers. 
Comparison of the haplotypes of the disease alleles clearly indicated that ABCB6
lay telomeric to the critical GRACILE region (presented in table 1 in III). 
BCS1L sequence analysis in the British patients 
We also sequenced the BCS1L using the DNA samples of the three 
British infants (Morris et al. 1995), whose disease course closely resembled that of 
the Finnish patients with GRACILE syndrome. The different BCS1L mutations 
identified in this study and previously (de Lonlay et al. 2001) are summarized in 
figure 7A and table 6. 
British patient 1 was a compound heterozygote for a premature stop 
codon at amino acid position 56 in the second exon, and for a V327A missense 
mutation in the seventh exon. Patient 2 had a heterozygous splice donor mutation 
changing the first G of the second intron to a T, and a heterozygous T>A single 
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Figure 7 
A) Genomic structure of the BCS1L gene, and all identified mutations (IV and Lonlay et al. 
2001). The sizes of the exons and introns are indicated as base pairs. The sizes of the first 
exon and the first intron (marked with asterisks) vary due to alternative splicing. B) The 
BCS1L polypeptide of 419 amino acid residues. The numbers indicate the polypeptide 
regions encoded by distinct exons of the BCS1L gene. Residues 9-32 correspond to the 
transmembrane region of the yeast BCS1p protein (Fölsch et al. 1996). Residues 224-344 
represent the conserved AAA domain, according to the CD-Search (Marchler-Bauer et al. 
2002) at NCBI’s BLAST service (AAA-ATPases Associated with a variety of cellular 
Activities). 
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nucleotide change in the middle of the first intron, 588 bp upstream from the start 
codon of the BCS1L. Patient 3 was a compound heterozygote for two missense 
mutations: the Finnish S78G mutation in exon 2, and an R144Q mutation in exon 
3. None of these mutations, including the intronic T>A change in patient 2, was 
found in 140 controls, 90 of whom were Finnish and 50 were other Caucasians.  
Genomic structure of BCS1L (IV)
Both the mRNA sequence and the genomic structure of the BCS1L gene
have been published earlier (Petruzzella et al. 1998; de Lonlay et al. 2001). 
However, the genomic sequence published by de Lonlay et al. was partially 
incomplete for the non-coding part of the first exons, which we determined using 
biocomputing tools. Comparison of the different EST and mRNA sequences 
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suggested that the 5’end of the BCS1L transcript can be alternatively spliced. The 
15 EST or mRNA sequences found in public databases and Celera represented six 
different splice variants. Two of the variants were represented several times and 
had been found in clones originating from normal tissues, whereas the other four 
were rare and reported only in EST libraries of cancer tissues, or had a non-
specified tissue origin in the databases. In most transcripts, the first exon was small 
(20-120 bp), and the size of the first intron varied from 800 to 1200 bp. The second 
exon was 369 bp, started 49 bp before the start codon, and contained an in-frame 
stop codon 42 bp upstream from the start codon. This exon and all six exons 
thereafter were identical in all the splice variants (figure 7A). A few clones 
contained an additional short exon in the middle of the first intron. The exons 
spanned 3.4 to 3.8 kb of the genomic sequence, and the size of the spliced 
transcript varied from 1.4 kb to 1.5 kb. The coding region was 1260 bp, encoding a 
polypeptide of 419 amino acids (Petruzzella et al. 1998).
The splice variants found by comparing the EST and mRNA clone 
sequences are not likely to affect the structure of the translated BCS1L 
polypeptide, since the second exon containing the start codon and all six exons 
thereafter are identical in all splice variants. It is also unlikely that alternative 
5’UTRs would affect the translation initiation, because an in-frame stop codon lies 
42 bp before the start codon, making earlier translation initiation impossible. The 
use of a methionine further downstream as an alternative start codon is not likely 
either, since the next methionine is residue 48, which is located downstream from 
the only transmembrane domain of the protein. Alternative splicing of the 5’UTR 
could, however, enable tissue-specific up- or downregulation of BCS1L expression.
The occurrence of the splice variants in different tissue and cell types and their 
importance for the regulation of gene expression remains to be verified by 
experimental tools. 
Functional consequences of the S78G mutation on BCS1L (IV) 
Expression, targeting, and stability of the mutant BCS1L
It has previously been shown that the human BCS1L protein is targeted 
unmodified to the inner mitochondrial membrane in vitro (Petruzzella et al. 1998). 
To study the effect of the S78G mutation on the synthesis, targeting and stability of 
the BCS1L protein, we subcloned the coding region of both wild-type and mutant 
BCS1L cDNA:s into the pCMV5 expression vector with a C-terminal FLAG tag. 
Intracellular targeting of the wild-type and mutant BCS1L polypeptides was 
studied in transiently transfected COS-1 cells by immunofluorescence microscopy. 
Staining with the anti-FLAG antibody completely overlapped with the 
mitochondrial staining both in the cells transfected with the wild-type construct and 
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in those transfected with the mutant construct (figure in IV), indicating that the 
S78G mutation does not influence the mitochondrial targeting of the BCS1L 
protein in vitro.  
Western blot analysis of the transiently transfected cell lysates revealed a 
single ~46 kDa polypeptide. There was no obvious difference in size or intensity 
between the signal from the wild-type and mutant polypeptides (figure in IV), 
suggesting that the S78G mutation does not affect the synthesis or posttranslational 
modifications of the BCS1L polypeptide. Pulse chase experiments were carried out 
to monitor the stability of the mutant BCS1L protein. The half-life of the FLAG-
tagged wild-type BCS1L polypeptide was 41 h, whereas that of the S78G mutant 
was only 14 h, suggesting that the S78G mutation decreases the stability of the 
BCS1L polypeptide in vitro (figure 8). 
Figure 8 
Stability of the wild-type and S78G mutant BCS1L polypeptides (IV). Transiently 
transfected COS-1 cells were pulse-labeled for one hour and chased for 0, 12, 24, 36 and 48 
hours. The BCS1L polypeptides were immunoprecipitated, separated on 10% SDS-PAGE 
and visualized by fluorography. The radioactive bands were quantified by densitometry. 
The results are presented as  percentages of the values at 0 h chase. The values on the curve 
are average values of duplicate experiments, with error bars showing the standard 
deviation.  
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Yeast complementation studies
Yeast BCS1p protein has been shown to be essential for the assembly of 
the mitochondrial respiratory chain complex III (Nobrega et al. 1992; Cruciat et al. 
1999). Yeast strains deleted for the BCS1 gene cannot grow on glycerol, since on 
non-fermentable carbon sources, yeast cells are dependent on oxidative respiration. 
On glucose, however, BCS1 deletion strains are able to grow utilizing anaerobic 
metabolism. Human BCS1L protein is highly homologous with yeast BCS1p 
protein (50% identity), and human BCS1L can partially rescue a yeast strain 
deleted for BCS1 (de Lonlay et al. 2001). This facilitated the use of yeast 
complementation studies in monitoring the functional effects of the S78G 
mutation.  
We tested the effect of the S78G mutation on the ability of human 
BCS1L to restore oxidative respiration in a BCS1 deletion strain. The BCS1
deletion yeast strain Y14211 was transformed with the wild type and 232A>G 
(S78G) mutant BCS1L cDNAs in a high-copy yeast expression plasmid pRS425. 
As a positive control, we also transformed the same strain with the wild-type yeast 
BCS1 cDNA in the same vector, and as a negative control we used the plain vector. 
The purified transformants were streaked on YPEG (ethanol-glycerol), YPD and 
SD plates without leucine (vector selection), and incubated at 30ºC and 37ºC. On 
YPD and SD-leu plates all the transformants grew equally well at both 
temperatures, indicating that they were all viable on glucose. On YPEG plates, the 
yeast BCS1 transformants were clearly growing after 48 h incubation. The wild-
type human BCS1L transformants grew, but considerably more slowly, showing the 
first signs of growth after four days at 37ºC, and after six days at 30ºC. The S78G 
mutant and the vector-only transformants did not show any growth, even after 
incubation for two weeks (figure 9). This suggested that the S78G mutation 
disturbs the function of BCS1L.  
Activity measurements of complex III in the Finnish GRACILE patients
One would expect that patients with BCS1L mutations would have 
decreased complex III activities in mitochondria. In the tissue samples of the three 
British patients (mutations identified in this study) and the five Turkish patients 
(mutations published earlier), the complex III activities have been shown to be 
decreased (Birch-Machin et al. 1989; Morris et al. 1995; de Lonlay et al. 2001). 
However, the Finnish GRACILE patients have been shown to have normal 
complex III activities in isolated mitochondria of all the tissues studied, and studies 
of oxygen consumption have also implied normal respiratory chain function 
(Fellman et al. 1998). Since it was surprising that the complex III activity seemed 
normal in the Finnish patients, we used all the available material and methods to  
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Figure 9 
Yeast complementation experiment with BCS1L (IV). The BCS1 deletion yeast strain was 
transformed with the wild-type and mutant BCS1L constructs in a high-copy yeast 
expression plasmid, pRS425. The wild type yeast BCS1 cDNA in the same vector was used 
as a positive control, and the plain vector as a negative control. A) YPEG (ethanol-glycerol) 
plate incubated at 30ºC for 11 days. B) YPEG plate incubated at 37ºC for eight days. C) 
YPD (glucose) plate incubated at 30ºC for three days. 
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confirm it. The detailed results of the biochemical analyses are presented in the 
tables 3-5 in IV. 
For respiratory chain enzyme activity measurements, fresh biopsy 
samples generally give the most reliable results, and we had appropriate age-
matched controls available for muscle biopsy specimens. The respiratory chain 
enzyme activities measured in isolated mitochondria from skeletal muscle biopsies 
of five Finnish patients were within the normal range. Since these activities 
represented the values of indirect measurements of complex III, deduced from the 
combined activities with complex I and complex II, we also assessed complex III 
separately, using a deep frozen skeletal muscle sample from one patient. This 
sample showed moderately decreased complex III activity, being reduced by 1.5 
SD from the controls’ mean, in proportion to the citrate synthase activity. If this 
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reduction is not a post-mortem artefact due to a tissue preservation problem and 
reduced enzyme activities, then this mild decrease might have remained undetected 
in the indirect complex III analyses of the biopsy specimen. 
Nuclear gene defects causing mitochondrial disorders often have a 
strictly tissue-specific expression (Papadopoulou et al. 1999). In the GRACILE 
syndrome the most relevant tissue for expressing complex III deficiency would be 
liver, since it is the major organ of dysfunction. The respiratory chain enzyme 
activities, including the separate assessment of complex III, were measured in 
tissue homogenates of deep frozen liver samples from three patients. In two of 
these samples all the mitochondrial enzyme activities were low, indicating a tissue 
preservation problem. However, in one liver sample the activities were in general 
within the normal range, and complex III also showed normal activity. Enzyme 
activity measurements carried out with isolated mitochondria from fresh liver 
specimens of four patients, obtained at autopsy shortly after death, also supported 
this finding by showing the presence of complex III activity. Unfortunately, 
appropriate controls for the fresh liver samples were not available, and thus fully 
reliable conclusions regarding these samples are not possible. 
Respiratory chain enzyme activities were also measured in mitochondria 
isolated from myocardial, brain and kidney specimens of four patients. The tissue 
samples were obtained shortly after death, and the results did not indicate a 
complex III defect. Unfortunately, appropriate controls were available only for the 
myocardial samples and, regarding the other tissues, these results should be 
considered with caution. 
Measurements of respiratory chain enzyme activities are highly sensitive 
to variations in experimental conditions (Thorburn 2000). They require fresh tissue 
specimens, or at least very well preserved deep frozen samples. The measurements 
should preferably be carried out using the relevant tissue, since respiratory chain 
enzyme defects are highly tissue-specific. The enzyme activities can show 
variation even within one tissue. Because healthy individuals show wide variation 
in the activities, the laboratories performing the measurements have to accumulate 
several matching controls. Especially regarding the complex III activity, 
measurements are notoriously difficult, and therefore some diagnostic laboratories 
routinely use combined (I+III, II+III, II and IV) measurements, whereas others 
consider separate measurement of complex III more accurate. For these reasons, it 
is not possible to draw definite conclusions concerning the complex III activity 
measurements of the Finnish GRACILE patients. If the patients were observed 
individually, and it were asked whether the results of respiratory chain enzyme 
activity measurements could explain the symptoms of the patients, the answer 
would definitively be that all the enzyme activities are within the normal reference 
range. However, when the Finnish GRACILE patients are viewed as a group, the 
61
complex III activities have a tendency to be more often in the lower than in the 
higher half of the control range. Thus, we can quite certainly exclude a severe 
complex III defect in the Finnish patients, but not a mild reduction in activity. Even 
a mild defect could contribute to the lactic acidosis and other symptoms, but is very 
unlikely to explain them all. This suggests that BCS1L has some other, at present 
unknown, vital function in addition to complex III assembly. 
Pathogenicity of the identified BCS1L mutations (IV) 
Our conclusion that the S78G amino acid change in BCS1L really is a 
causative mutation, and not merely a harmless polymorphism, is based on sequence 
analyses of the Finnish and British patients and controls, as well as on the results of 
the pulse chase experiments and the yeast complementation studies. 
The S78G mutation identified in the Finnish patients with GRACILE 
syndrome segregated without exception with the disease phenotype in all the 
families. Only one carrier of the mutation was found in the 544 control individuals 
screened, supporting the causative role of the mutation. The predicted effect of the 
serine-to-glycine change on the polypeptide is also considerable. Glycine, the 
smallest amino acid, enables the polypeptide backbone to make turns that are 
impossible with any other residue, and it lacks the hydroxyl group and the polarity 
of serine. S78 is also highly conserved across the species, implying that the amino 
acid residue is functionally important. (Comparisons between the amino acid 
sequences of different species were performed with the BLAST programs at NCBI 
and with the MultAlin alignment program (Corpet 1988).) On the other hand, both 
serine and glycine are small, uncharged amino acids, and a single amino acid 
change of this kind could also be a rare SNP occurring in the founder chromosome, 
located in the immediate vicinity of the real mutation and thus segregating with the 
disease phenotype. Therefore, additional evidence of the causative character of the 
S78G change was needed. 
In a patient group with an identical or similar disease course, 
identification of different mutations in one gene can confirm the pathogenicity of 
the mutations. It was not possible to obtain this kind of proof by studying the 
Finnish GRACILE families, since they all carried the same founder mutation. 
However, sequence analysis of the three British patients (Morris et al. 1995), 
whose disease course closely resembled that of the Finnish GRACILE patients, 
revealed five different BCS1L mutations, including the Finnish S78G mutation.  
The S78G mutation had functional consequences also. In the pulse chase 
experiments performed in COS-1 cells, the half-life of the mutant BCS1L was only 
one third of that of the wild-type polypeptide. This indicated that the amino acid 
change resulted in decreased stability of the protein. The effect could be 
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cumulative in vivo, leading to drastically decreased BCS1L levels in the patient 
tissues. On the other hand, a cellular feedback mechanism could increase the 
expression of the mutated BCS1L, and thus compensate for the accelerated 
degradation of the protein. Therefore the impact of the shortened half-life of the 
mutant BCS1L in the disease pathogenesis remains an open question.  
The mutant human BCS1L was not able to rescue the yeast strain deleted 
for BCS1, whereas the wild-type human BCS1L was. This indicated a clear 
difference in function between the wild-type and the S78G mutant proteins. This 
result was interesting, since the growth defect in the BCS1 deletion strain is 
probably caused by impaired complex III function, but the S78G mutation does not 
seem to affect complex III in human tissues. This suggests that BCS1L involves the 
mitochondrial respiratory function through some other mechanism also, in addition 
to complex III assembly. On the other hand, the wild-type human BCS1L was only 
partially able to complement the BCS1 deletion yeast, and therefore the 
consequences of the S78G mutation on the respiratory chain may have appeared 
more serious in yeast complementation experiments than they are in vivo. 
The pulse chase and yeast complementation experiments further 
supported the causative role of the Finnish S78G mutation. However, the 
identification of different mutations in the British patients, and especially the fact 
that one of the British infants was a compound heterozygote for the Finnish 
mutation and another mutation, provided the most convincing data confirming the 
pathogenic nature of the S78G mutation.  
The pathogenicity of the individual British mutations has not yet been 
formally proved, but very likely the early stop mutation, the splice site mutation, 
and the R144Q and V327A missense mutations are pathogenic. These mutations 
were not present in the 140 controls screened. Unfortunately, no British controls 
were available, but screening of a control panel of 50 Caucasian individuals with 
ancestry in different parts of Europe, and additionally of 90 Finns, quite well 
excluded the possibility that the observed nucleotide variants were just common 
polymorphisms. The premature stop codon is a truncating mutation and can be 
considered pathogenic even without functional evidence. The functional
significance of most of the other mutations is also obvious: The splice site mutation 
abolishes a classical splice donor consensus sequence, and is thus likely to result in 
intron retention and truncation of the protein. The R144Q mutation changes a basic 
and charged arginine into an acidic and uncharged glutamine. R144 is conserved in 
the mouse, and in both Drosophila melanogaster and Saccharomyces cerevisiae it 
is relatively well conserved, being replaced by lysine, another basic and charged 
amino acid. The V327A change appears the least dramatic of the current mutations, 
since both valine and alanine are small, nonpolar amino acids without functional 
groups. V327 is not strictly conserved either, since in Saccharomyces cerevisiae it 
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is replaced by threonine, a polar amino acid. However, since the early stop 
mutation found in the other allele of the same patient is an obligatory mutation, we 
consider this V327A substitution a likely mutation as well. 
The importance of the heterozygous single nucleotide change in the first 
intron of BCS1L in British patient 2 is questionable. It was not present in 140 
controls, implying that it does not represent a common SNP. However, the 
functional importance of the region is not supported by the phylogenetic 
conservation, since the 20 base pairs surrounding the nucleotide variant are not 
conserved in the mouse. In her other allele, the patient had the splice site mutation, 
which was heterozygous as well, but we did not identify any other possible 
mutations in the DNA of this infant. However, we cannot exclude the possibility of 
a regulatory mutation located far upstream. 
Phenotype heterogeneity of the BCS1L mutations (IV) 
All the Finnish GRACILE patients had the same homozygous BCS1L
mutation, whereas the three British patients were compound heterozygotes for 
different mutations. The sequence analysis of the five patients with Turkish origin 
(de Lonlay et al. 2001) had previously revealed four other BCS1L mutations, all 
being missense mutations. The symptoms of the patients with the different BCS1L
mutations are summarized in table 6. The common clinical characteristics of the 
patients included lactacidosis, tubulopathy, liver dysfunction and cholestasis. Fetal 
growth retardation was severe in the Finnish patients and moderate in the British 
infants, but only slight or non-existent in the Turkish patients. The Finnish patients 
had normal muscle tonus and no neurological or neuropathological abnormalities, 
whereas all the Turkish patients except one had severe neurological problems: One 
baby with the S277N mutation had encephalopathy with deafness and blindness, 
and her sister, who was alive at the age of nine years, had cerebral atrophy and 
severe psychomotor retardation. The Turkish infants with the P99L mutation had 
progressive neurological problems as well, including ventilation abnormalities of 
neurological origin and brainstem lesions compatible with Leigh syndrome. The 
British patients had muscle hypotonia and one of them developed seizures and 
coma at the age of one day. All the Finnish and British infants died before the age 
of five months, half of them already during the first days of life. The Turkish 
patients survived, on average, longer. One essential difference in the clinical data 
of the patient groups was that the respiratory chain complex III activities of the 
Finnish patients were within the normal range, whereas the other patients showed 
clearly decreased complex III activities in enzyme activity measurements. 
Unfortunately, iron metabolism was not studied in either the British or the Turkish 
patients. Thus, we do not yet know whether the abnormalities in iron metabolism 
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Table 6 
Comparison of the symptoms caused by different BCS1L mutations. 
BCS1L 
mutation(s) a
S78G R56STOP and  
V327A 
Splice site mutation 
and an intronic 
nucleotide change b
Number of patients 17 (11 families) 1 1 
Origin of the 
patient(s) 
Finnish British British 
Male / female 5/12 m f 
Birth weight, g median 1560 2020 1830 
Birth length, cm median 43 47 45 
Head circum- 
ference, cm 
median 31 31 31 
Gestational age, 
weeks
median 38 38 39 
Age at death 1 day – 4 months 2 days 1 month 
Lactacidosis yes yes yes 
Tubulopathy  yes yes yes 
Iron overload yes ? ? 
Cholestasis yes no yes 
Liver dysfunction yes ? yes 
Muscle hypotonia no yes yes 
Neurological 
symptoms
no seizures and coma  no 
Complex III 
activity 
normal c decreased decreased 
References  Fellman et al. 1998, 
Rapola et al. 2002, 
IV
Birch-Machin et al. 
1989, Morris et al. 
1995, IV 
Morris et al. 1995, IV 
a  If one mutation mentioned, the patients are homozygous for that mutation. If two different 
mutations, the patients are compound heterozygotes. 
b Pathogenicity of these intronic nucleotide changes has not been confirmed. 
c The enzyme activities are within the normal range, but a mild defect cannot be excluded. 
observed in the Finnish patients were characteristic of the S78G mutation only, or 
whether the other mutations in BCS1L would also cause similar findings. 
It is not uncommon for different mutations in one gene to cause different 
disease phenotypes. For example, different mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene can result in typical cystic 
fibrosis, characterized by severe lung disease, pancreatic exocrine insufficiency, an 
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S78G and R144Q S277N P99L R155P and V353M 
1 2 (siblings) 2 (not related) 1 
British Turkish Turkish Turkish 
f f  m / f m 
1840 2490 / 2940 2340 / 2620 3330 
48 46 / 48 46 / 49 53 
31 31  ? ? 
38 38 / 39 40 / 41 39 
3 months 3 months / alive 
when 9 years old  
6 months / 2 years alive when 5 months 
old 
yes yes  yes yes 
yes yes  yes yes 
? ? ? ? 
yes yes  ? ? 
yes yes  yes yes 
yes ? yes / ? ? 
no severe 
encephalopathy 
Leigh Syndrome  no 
decreased decreased decreased decreased 
Morris et al. 1995, 
IV
de Lonlay et al. 
2001 
de Lonlay et al. 
2001 
de Lonlay et al. 
2001 
increase in the concentration of sweat electrolytes, and male infertility, or solely 
male infertility with no other symptoms (Stuhrmann and Dork 2000). However, the 
BCS1L mutations cannot (at all) be grouped as “severe” and “mild” mutations. If 
the degree of fetal growth restriction or the survival time of the patients were the 
criteria, the Finnish and British mutations would be the most severe. However, 
considering the neurological problems, one British and four Turkish patients were 
seriously ill, whereas two British babies only had muscle hypotonia, and the 
Finnish infants were asymptomatic. Interestingly, muscle hypotonia and 
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neurological problems, for example encephalopathy, seizures and Leigh syndrome, 
are typical of mitochondrial disorders, and the occurrence of these symptoms 
correlated with decreased complex III activity in measurements of respiratory chain 
enzyme activities. One tempting explanation for this kind of variation in the 
symptoms and findings caused by BCS1L mutations would be that the human 
BCS1L protein has a dual function. Some BCS1L mutations essentially disturb the 
complex III assembly, whereas other mutations, for example the Finnish S78G 
mutation, severely damage the other, at present unknown, function of the BCS1L. 
Probably most of the mutations affect both functions to some extent. So far, BCS1L
mutations are the only nuclear gene defects described that involve the function of 
complex III, and thus we cannot compare the consequences of the BCS1L
mutations with isolated complex III defects. The published complex III defects 
(Andreu et al. 1999; Valnot et al. 1999; Keightley et al. 2000; Legros et al. 2001; 
Wibrand et al. 2001) have been caused by sporadic, heteroplasmic mutations in the 
mitochondrial cytochrome b gene, the situation being different compared to 
autosomal recessive inheritance.  
What other type of function could BCS1L perform? The best known 
function of mitochondria is to supply cellular energy, but mitochondria perform 
numerous other tasks as well. One of the vital mitochondrial functions is the 
assembly of FeS clusters (Lill and Kispal 2000; Muhlenhoff and Lill 2000), which 
serve as electron carriers in the mitochondrial respiratory chain, and as important 
cofactors in several other proteins located in the mitochondria, cytosol and nucleus. 
Some ten mitochondrial proteins involved in the synthesis and transfer of the FeS 
clusters have been identified in Saccharomyces cerevisiae so far, but the details of 
this machinery are still largely unknown. It is an interesting question, whether 
BCS1L has a role to play in the synthesis or transport of FeS proteins in general, in 
addition to the fact that it is known to be necessary for correct assembly of the 
Rieske protein subunit, which also contains an FeS cluster, to the complex III.   
Presumably, the function of BCS1L is linked with cellular iron 
metabolism, since at least the Finnish patients with the homozygous S78G 
mutation have a marked iron overload. Iron metabolism is tightly regulated, since 
iron is an essential cofactor in various cellular processes, but free iron is toxic 
because of its propensity to induce the formation of free radicals (Andrews 2000; 
Walker et al. 2001). A few mitochondrial diseases associated with disturbances in 
cellular iron metabolism have been described to date: X-linked sideroblastic 
anemia, X-linked sideroblastic anemia with ataxia and Friedreich ataxia (Andrews 
2000). Like the GRACILE syndrome, they are caused by mutations in nuclear 
genes, but both their clinical and their histological picture are different. They are 
characterized by iron accumulation inside mitochondria, whereas, in electron 
microscopy of liver and skeletal muscle specimens, the mitochondria of GRACILE 
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patients appear normal (Rapola et al. 2002). The excess iron in the hepatocytes is, 
instead, stored in cytosolic hemosiderin granules and ferritin particles. BCS1L 
could possibly be involved in iron transport from the cytosol to the mitochondria. 
On the other hand, it is possible that the abnormalities of iron metabolism in 
GRACILE patients are secondary to the liver disease, and that there is no direct 
link between BCS1L and cellular iron traffic. 
DNA diagnostics of the GRACILE syndrome (I, II, IV) 
The assignment of the GRACILE locus already enabled linkage-based 
prenatal diagnostics for families with at least one previously affected child. Now 
the Finnish S78G mutation can be directly identified, and DNA diagnosis is 
possible also in families without a previously affected baby. A specific diagnosis 
can help to avoid unnecessary diagnostic tests and is psychologically important for 
the parents. In addition, the mutation-based DNA diagnostics enables reliable and 
easy carrier diagnosis for healthy siblings and other relatives, as well as for their 
spouses, making genetic counselling easier. 
Prenatal diagnosis early in pregnancy is possible only if the carrier state 
of the parents is known in advance. Otherwise, the disease cannot be suspected 
until the end of the second trimester, when fetal growth retardation can be detected 
by ultrasound. However, even later in pregnancy a reliable DNA diagnosis of the 
GRACILE syndrome can be helpful, because it can prevent an unnecessary 
caesarean section by explaining the reason for the fetal growth retardation.  
For non-Finnish patients, the sequence analysis of the BCS1L gene is a 
diagnostic option. So far, all Finnish GRACILE patients have had the same S78G 
founder mutation, but it is likely that other, rare mutations exist also in Finland. 
Thus, if BCS1L mutations are suspected on the basis of the patient’s symptoms, 
but the patient does not have the S78G mutation, or is heterozygous for it, 
sequencing of the BCS1L gene should be considered for Finnish patients also.  
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CONCLUDING REMARKS 
In this study, we localized the causative gene for the GRACILE 
syndrome using linkage, linkage disequilibrium and ancestral haplotype analyses, 
and then identified the causative gene by analyzing the positional candidates in the 
critical chromosomal region. This project was started in 1996, when the use of 
microsatellite markers was routine and dense genetic maps were available in 
databases. Also, many genes and thousands of ESTs had been sequenced and 
localized to human chromosomes. Nevertheless, positional cloning projects of 
monogenic diseases were laborious. After initial localization of the GRACILE 
locus in 1997, we performed RH mapping of the critical markers to be able to 
determine exactly the critical chromosomal interval, and to create the basis for a 
physical map of the region. However, when the RH mapping was completed, the 
HGP was speeding up both the large-scale sequencing of the human genome and 
the identification of the genes, and traditional physical mapping in this project 
turned out to be unnecessary.  
Nowadays, the positional candidate approach has practically replaced 
“pure” positional cloning. When a disease locus has been identified, the sequences 
of positional candidate genes are available in internet databases. If the sequence of 
a critical region is not complete, the physical map can be built by biocomputing 
methods, and new genes are cloned mostly “in silico”. A huge amount of 
laboratory work can be avoided, as compared with the situation five years ago. 
Mapping and identification of a disease gene for a monogenic disorder can be 
perfectly straightforward and take only a few months. In many cases, however, it is 
still not easy. First, the sequencing of the human genome is not yet totally 
completed, for there are still gaps in the sequence. Secondly, although genes, 
especially their coding regions, can be identified fairly easily with gene prediction 
programs and by comparing genomic and EST sequences, the exact structure of 
many genes is not yet known. The regulatory regions of the genes, and their 
function, are for the most part still unidentified. In this study we observed several 
different splice variants of the 5’UTR of the BCS1L, but we do not know anything 
yet about the regulation or significance of the variable splicing. The same is true of 
many genes, concerning also the coding regions: the surprising result of the 
analysis of the initially sequenced human genome was the small total number of 
human genes, while the commonness of variable splicing contributes to the 
diversity of the human proteins.  
Identification of the disease gene provides the starting point for revealing 
the pathogenesis of the GRACILE syndrome. Surprisingly, the respiratory chain 
complex III activities were normal or only slightly decreased in the Finnish 
GRACILE patients, despite the BCS1L mutation. This suggested that BCS1L has 
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another, as yet unknown, function, in addition to complex III assembly. Further 
studies of the BCS1L should address the interesting question of how the S78G 
mutation in BCS1L can cause a lethal disease without considerably affecting 
complex III function. So far, only two functional domains of BCS1L have been 
recognized (figure 7B). Residues 224-344 represent the conserved AAA domain, 
and residues 9-32 are hydrophobic and correspond to the transmembrane region of 
the yeast Bcs1p. Two of the missense mutations so far identified in BCS1L are 
located in the AAA domain, whereas four mutations, including the Finnish S78G 
mutation, lie between the transmembrane and AAA domains. The functional 
domains of this part of the protein remain to be characterized and could potentially 
be associated with the as yet uncharacterized function of BCS1L. Our other 
hypothesis is based on the pulse chase experiments, which revealed that the S78G 
mutation accelerates the degradation of BCS1L in vitro. If this were also to result 
in decreased protein levels in tissues in vivo, without the mutation interfering in 
protein conformation, the reduced amount of protein in the mitochondria might be 
sufficient to perform complex III assembly, whereas the other function could be 
compromised.  
Identification of the gene defect underlying the GRACILE syndrome 
provides a starting point for more detailed studies of the function of BCS1L and 
proteins interacting with it in cellular energy and iron metabolism. From the 
clinical point of view, this study has produced DNA diagnostics for this lethal 
disease, enabling prenatal diagnosis and carrier testing in Finnish GRACILE 
families.  
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ELECTRONIC DATABASE INFORMATION
Internet databases are essential tools of molecular genetics, and an increasing 
number of references in the literature are nowadays provided as electronic 
references, instead of traditional printed ones. Internet addresses for the databases, 
programs and organizations mentioned in the text are provided below. 
BLAST service at NCBI, http://www.ncbi.nlm.nih.gov/BLAST/ 
Celera, http://www.celera.com  
Electronic PCR at NCBI, http://www.ncbi.nlm.nih.gov/genome/sts/epcr.cgi 
European Bioinformatics Institute (EBI), http://www.ebi.ac.uk/ 
GenBank at NCBI, http://www.ncbi.nlm.nih.gov/Genbank/  
Genethon, http://www.genethon.fr/php/index.php 
The Genetic Location Database (LDB) of University of Southampton, 
http://cedar.genetics.soton.ac.uk/public_html/ldb.html 
Genome Data Base (GDB), http://gdbwww.gdb.org/ 
Human Genome Organization (HUGO), http://www.gene.ucl.ac.uk/hugo/ 
The Map Viewer at NCBI, http://www.ncbi.nlm.nih.gov/cgi-bin/Entrez/hum_srch 
Multalin alignment program, http://prodes.toulouse.inra.fr/multalin/multalin.html 
National Center for Biotechnology Information (NCBI), 
http://www.ncbi.nlm.nih.gov/ 
National Human Genome Research Institute (NHGRI), http://www.genome.gov/ 
National Institutes of Health (NIH), http://www.nih.gov/ 
A new gene map of the human genome at NCBI (GeneMap’98), 
http://www.ncbi.nlm.nih.gov/genemap99/  
Online Mendelian Inheritance in Man (OMIM), 
http://www.ncbi.nlm.nih.gov/Omim/  
Sequence utilities of the Search Launcher at Baylor College of Medicine (BCM), 
http://searchlauncher.bcm.tmc.edu/seq-util/seq-util.html 
The SNP database (dbSNP) at NCBI, http://www.ncbi.nlm.nih.gov/SNP/ 
Stanford Human Genome Center (SHGC), http://shgc-www.Stanford.edu/ 
University of California Santa Cruz (UCSC) Genome bioinformatics, 
http://genome.ucsc.edu/ 
Whitehead Institute, http://www-genome.wi.mit.edu/ 
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